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 Abstract 
Intimal hyperplasia (IH) is a prevalent vascular disease characterized by lesion formation on             
blood vessels, usually through cell growth at the site of an injury. Creating a tissue engineered blood                 
vessel (TEBV) with intimal hyperplasia would serve as an ​in vitro disease model which would enhance                
and expedite drug testing. Though such an ​in vitro model has yet to be engineered, it may be achieved by                    
incorporating growth factor-releasing microspheres into a localized region of the TEBV. The team was              
tasked with designing microspheres that can release growth factor to stimulate the formation of a lesion                
by localized cell proliferation in the established blood vessel model. Four materials (gelatin, chitosan,              
PLGA, and silk) were selected as options for the microsphere design. Each material was fabricated and                
tested to determine compliance with established design objectives and constraints, and silk was ultimately              
chosen as the superior material for use in the TEBV intimal hyperplasia model. In conducting an MTT                 
assay to ensure the materials were biocompatible with smooth muscle cells, silk, like the other materials,                
induced only a slight reduction in cellular metabolic activity. Additionally, silk showed the most              
consistent size distribution characterized by scanning electron microscopy. Microspheres were tested for            
encapsulation efficiency of lysozyme, an analog protein, by running a lysozyme activity assay on a               
dissolved sample of loaded microspheres. Silk showed a greater encapsulation efficiency than the other              
tested material, chitosan. Also, results from the release assay suggest active lysozyme is released from               
silk microspheres in media suspension over the course of seven days, showing silk’s potential to release                
active protein. It is suggested that continued encapsulation and release testing be done on new               
microsphere batches loaded with growth factor and that overall functionality of the microspheres be              
assessed once incorporated into the TEBV to analyze the potential of the design for the intended                
application.  
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 1. Introduction  
After surgical modification or damage to a blood vessel, smooth muscle cells (SMCs) comprising              
the muscular layer of the impacted blood vessel walls often grow inward and close the vessel. This                 
phenomenon, known as intimal hyperplasia (IH), precludes normal blood flow due to the formation of a                
lesion which heightens the risk of a patient sustaining a blood clot and impedes the passage of blood to                   
the affected organs. Endothelial cells (ECs) lining the vessel interior may initiate this increase in SMC                
proliferation due to improper stimuli, such as abnormal blood flow patterns imposing larger wall stresses               
than metabolically necessary (Zhang et al., 2018). This impeded blood flow can reduce the supply of                
oxygen delivered to tissues which commonly results in tissue necrosis (Mylonaki et al., 2016). IH               
commonly arises in blood vessel corrective procedures, wherein attempts to widen the vessel fail over               
time and the vessel narrows once more, a condition known as restenosis. Among common blood vessel                
interventions, as many as 50 percent of angioplasties fail due to intimal hyperplasia and restenosis               
(Glagov, 1994; Collins et al., 2012).  
Currently, few FDA approved drugs exist for treatment of IH progression, mainly due to an               
inadequate understanding of the mechanism of the condition (Mylonaki et al, 2016). To remedy this               
shortage of clinical treatments, studies of potential drug delivery options are ongoing. Current in vivo               
models, however, have mainly utilized non-human models, such as rats, wherein vessels are artificially              
narrowed through atherosclerosis, the abnormal accumulation of cholesterol within the animal’s           
vasculature (Hui, 2010). Additionally, rat vessels exhibit different flow patterns and histology than those              
in humans, making them a poor model for mirroring human IH (Hui, 2010). To better emulate IH in                  
humans, blood vessels composed of human-sourced cells are needed, as they can better recapitulate the               
characteristics of human blood vessels seen ​in vivo​.  
​In vitro disease or organ models are valuable in drug testing, because they do not face the same                   
ethical issues as using ​in vivo ​models and still provide a biological structure that accurately simulates ​in                 
vivo capabilities. Tissue-engineered blood vessels (TEBVs), in addition to serving as an accurate model of               
in vivo vasculature, can also provide greater control of morphology as an ​in vitro ​model of IH. Though                  
not yet successfully established, a TEBV that models vascular diseases has been highly sought throughout               
the field of tissue engineering in the hopes of enhancing and expediting drug testing. Synthesizing TEBVs                
in vitro​, ​has been accomplished a variety of different techniques, including three-dimensional (3D)             
bioprinting and self-assembly of 3D tissue rings. However, at this point uniform TEBVs, modeling              
healthy blood vessels, have been engineered, though only to serve as possible vessel replacements (Dahl               
et al., 2011; Hibino et al., 2010; Strobel et al., 2017).  
Specifically, an accurate, reproducible, ​in vitro IH model is needed. The lack of standardization              
of IH in current, non-human blood vessel models in different studies arises from the varying methods for                 
creating IH. The formed lesion produces an IH model whose parameters, such as vessel diameter and cell                 
counts, vary depending on the manufacturing process utilized (Hui, 2010). To remedy this lack of               
reproducibility, drug delivery devices, such as microspheres, can be explored. These microspheres can be              
derived from various techniques and can provide for localized dispersal of a loaded substance. For               
example, microspheres can be embedded in TEBV to disperse a drug molecule (​Alagusundaram et al.,               
10 
 2009​). Microspheres can be made with standardized protocols which can be altered to vary drug loading                
capacity and rate of degradation. With a variety of biocompatible materials of which to construct these                
vehicles, scalable amounts of a lesion-forming biologic can be loaded within. Biologics consist of a               
variety of organic substances such as artificial hormones, growth factors, and enzymes that can actively               
impact cellular biochemistry in its intended area of the body (Lochhead, 2012). For the stimulation of                
localized cell proliferation to model a lesion within the blood vessel, platelet-derived growth factor-BB              
(PDGF-BB) can be used to promote abnormal accumulation of SMCs into a vessel lumen (Hui, 2010;                
Collins et al., 2012). Microspheres loaded with vascular growth factors can be integrated into an ​in vitro                 
TEBV to trigger IH by releasing its load over time to vessel SMCs (Strobel et al., 2017). The Rolle Lab at                     
Worcester Polytechnic Institute currently utilizes a scaffold-free system that has been engineered to allow              
for the creation of TEBVs from SMCs differentiated from primary human smooth muscle cells. SMCs               
are seeded into ring-shaped agarose wells, in which the cells self-assemble into 3D toroids following an                
incubation period of 3 days. The toroid rings are then placed on top of each other to allow for toroid                    
fusion into a 3D tissue tube (Strobel et al., 2018).  
Previous research from the Rolle lab has indicated that gelatin microspheres have the ability to be                
incorporated within toroids of the TEBV (Strobel et al., 2018). During the TEBV fabrication process,               
gelatin microspheres were co-seeded into the agarose wells with the SMCs. Toroid fusion was still seen                
after the 3 day incubation period with the addition of the gelatin microspheres, and no difference in TEBV                  
formation was seen during this new fabrication technique. The study found that gelatin microspheres              
could be incorporated into focal regions of the TEBV successfully. Therefore, it was suggested in future                
studies that microspheres could be loaded with growth factors for inducing ​in vitro ​disease models               
(Strobel et al. 2018).  
In this project, the team aimed to create microspheres capable of releasing growth factor, that can                
be used to stimulate cell proliferation and IH lesion formation in a TEBV. Successful creation of the IH                  
model can be accomplished by culturing PDGF-BB-loaded microspheres with SMCs during the formation             
of a few toroids. These toroids containing microspheres can then be fused within normal TEBV rings,                
creating a vessel with microspheres embedded at a specific region. This region will begin to emulate a                 
lesion as the localized microspheres release PDGF-BB and the nearby cells are induced to proliferate               
(Strobel et al., 2018). Determining the best design for creating the growth-factor releasing microspheres is               
an important step in accomplishing this goal. An overall map of our project is shown in Figure 1. 
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     Figure 1:​ Project plan schematic. This study focuses on the portion framed by the black box. The 
team sought to develop microspheres capable of releasing growth factor to cause IH. 
In subsequent studies, the team found that gelatin microspheres degrade too quickly to allow for 
sustained PDGF release and IH lesion formation, so the focus of the team's project was to explore 
alternative microsphere materials. 
 
2. Literature Review  
2.1 Pathology  
IH arises as proliferative lesions form within arteries and veins (Collins et al., 2012). Both blood                
vessel types are composed of an exterior layer of structural collagen and compliant elastin. The               
dichotomy of these two opposite proteins confers varying resilience to a blood vessel in the tunica                
externa. Moving inwards, SMCs occupy the tunica media layer to control vessel dilation and contraction               
(Figure 2). Adjacent to the tunica media is the tunica intima, wherein simple squamous ECs interface with                 
blood cells and proteins (Galante et al., 2007; Collins et al., 2012)  
12 
  
Figure 2:​ Arterial Wall Anatomy (Blausen, 2014). 
In healthy patients, the tunica intima provides a sleek, non-thrombogenic surface upon which             
blood can flow, exhibiting a shear stress on this layer of about 15 dyne/cm² (Collins et al., 2012; Glagov,                   
1994). Wall thickness may vary based on the stress exhibited. If this stress is increased abnormally above                 
this shear stress value, the endothelial layer may sustain injury and excrete cytokines and oxidative               
species that can dilate the vessel and encourage SMC proliferation (Yau et al., 2015; Zhang et al., 2018).                  
In tandem, platelets may come into contact with the collagen layer beneath and, compounded with a                
thrombogenic protein called tissue factor produced by the tunica intima and tunica media layers, clot at                
the site of damage on the vessel wall (Yau et al., 2015). Upon its binding, in addition to interactions of                    
other blood clotting factors,  PDGF-BB is released by granules within the platelets (Yau et al., 2015).  
PDGF-BB is a molecule found within vascular systems which serves as a mitogen for connective               
tissue cells (Heldin & Westermark, 1999). Specifically, PDGF-BB has been shown to play a significant               
role in inducing the phenotypic change in SMCs from the mature contractile state to the proliferative state                 
associated with IH lesions (Zhao et al., 2011). PDGF-BB is present during embryonic development of the                
SMCs, allowing for the proliferation and growth of tissue vessels within the embryo. Following the               
increase of transforming growth factor-beta (TGF-β) expression within the system, expression of            
PDGF-BB decreases significantly, and PDGF-BB expression only increases during wound healing of the             
vascular tissue due to the need of increased proliferation of the injured cells (Heldin & Westermark,                
1999). Under physiological conditions, SMCs remain in a stable, contractile state. However,            
overexpression of PDGF-BB within mature vascular tissues in a normal healthy state promotes             
13 
 de-differentiation of SMCs into their proliferative state, leading to abnormal over-proliferation of the             
SMCs and the formation of lesions characteristic of IH ​in vivo​ (Huang et al., 2002; Collins et al., 2012).  
To treat this pathology, an ​in vitro model that mimics the stages of IH is needed. Before going                  
into clinical trials, the FDA mandates that the efficacy and utility of potential therapeutic in question be                 
demonstrated in lab experiments in Step 1 of their approval process (Carpenter, 2002). Therefore a robust                
system that is conducive to measuring a drug’s therapeutic efficacy, must be created. For IH, an ​in vitro                  
blood vessel system with defined lesions, induced by PDGF-BB, could serve as this model.  
2.1.1 Clinical Need 
Currently, no viable methods outside of surgery can fully treat or prevent IH. In both native and                 
grafted vessels, IH can arise from various molecular pathways and macroscopic factors, such as vessel               
injury and interaction with implanted polymer materials. Removing diseased portions of vessels or             
inserting stents can cause further injury to adjacent sites in the vessel, which can cause a recurrence of IH.                   
Indeed, up to 60% of vessel transplants experience IH (Collins et al., 2012). Moreover, current               
medications can only alleviate symptoms of IH, rather than treating the condition itself. Specifically,              
anticoagulants like warfarin can act to prevent blood clots within IH-impacted vessels but require              
long-term usage and can cause internal bleeding (Collins et al., 2012). Anti-inflammatory drugs can lower               
the expression of cytokines that cause IH, but may require continuous administration (e.g., injection) and               
only target specific cytokines, leaving other molecular signals unchecked (Collins et al., 2012). Therefore,              
given the current lack of cure for IH, further research into the pathology of the disease is needed for a                    
permanent remedy to the condition.  
2.2 Current Testing Models  
Modern models for simulating IH have involved artificial induction of IH within rodents for ​in               
vivo ​studies. Specifically, for ​in vivo studies, the development of atherosceloritic plaque inside blood              
vessels by suturing vessels with polymers like polypropylene (PPE) is one method to induce IH (Hui,                
2010; Mylonaki et al., 2016). For this method, the vascular endothelial layer is injured by introduction of                 
the PPE surface by cutting the vessel and sewing it to the polymer. By damaging the vessel wall, the                   
SMCs becomes exposed within the vessel and multiply inwards (Mylonaki et al., 2016). Moreover, the               
plastic graft can increase the presence of cytokines that can trigger vessel SMCs to undergo mitosis.                
These diseased vessels then need to be prepared for study by injecting the vessels with vehicles loaded                 
with vessel-dilating or blood-thinning medications. After adding tested drug, the studied vessel can be              
analyzed by various methods, including histological cross-sections, live cell staining, ELISA for SMC             
biomarkers, and microscopy (Mylonaki et al., 2016; Collins et al., 2012). A limitation with using ​in vivo                 
models is the lack of identical vasculature and blood composition between different tested animals,              
adding variability to results collected from the animal study  (Hui, 2010).  
An ​ex vivo ​technique involves removing IH-injured vessels from a cadaver or other species and               
preserving it in formalin and paraffin wax for vascular disease studies (Cizek et al., 2007). Though the                 
preserved vessels retain their structure and morphology, in formaldehyde, proteins within vascular cells             
will be fused by covalent bonds, blocking their active sites and rendering them nonfunctional (Venuti et                
14 
 al., 2004). Proteins within vascular SMCs must retain their natural structure for SMCs to thrive and not                 
die, so they can progress into IH (Mylonaki et al., 2016). Therefore, to study the development of IH for                   
drug screening within a living system, cells cannot be preserved in formaldehyde and paraffin.  
An additional shortcoming common to both types of models is a lack of reproducibility and ease                
of access. Intact vessels from cadavers and animals may be in short-supply, require special licensing and                
handling to utilize, and entail extraneous variables arising from the whole model organism that can skew                
analysis of a potential IH therapy (Cizek et al., 2007). Moreover, as current methods utilize vessels from                 
natural sources, their composition cannot be specifically controlled, the results from analysis of one blood               
vessel cannot be extrapolated accurately to describe other vessels, especially to human vessels if the               
vessel is derived from another species, such as a rat. A human model is thus needed for a more                   
streamlined, controlled approach, wherein vessels can be specifically tailored and created on-demand. 
2.3 Investigated Solutions  
There are currently multiple solutions which have been discussed that would allow for the              
formation of proliferative lesions within blood vessels (Hui, 2010; Mylonaki et al., 2016; Strobel et al.,                
2018). However, there is still a need for an improved system to induce proliferation of SMCs within a                  
TEBV to address aforementioned shortcomings in current ​in vivo ​and ​ex vivo models. Two popular               
solutions presented include genetic alteration of vessel SMCs and delivery of growth factors within the               
tissue rings through drug delivery systems such as microspheres. Growth factor delivery, specifically             
PDGF-BB and TGF-β, have been linked with characteristics of IH (Strobel et al., 2016). In both of the                  
investigated solutions presented, one of the growth factors has played a significant role in the anticipated                
formation of intimal hyperplasia lesions.  
2.3.1 Gene Altering  
One potential strategy to create IH lesions ​in vitro is through genetic alteration of the SMCs.                
Specifically, the ability to inhibit TGF-β signaling within SMCs could prove to play a role in inducing a                  
diseased state within vascular tissues. TGF-β consists of a family of cytokines that regulate cellular               
functions including growth, adhesion, migration, apoptosis, and differentiation (Guo & Chen, 2012). It             
has been hypothesized that TGF-β also plays a significant role in vascular development and SMC               
differentiation (Perrella et al., 1998). One of the main contributors to many cardiovascular disorders,              
including IH, is the abnormal differentiation of SMCs from their proliferative embryonic state to their               
contractile mature state (Guo & Chen, 2012). It has been shown that the TGF-β signaling pathway is one                  
of the main causes of this SMC differentiation.  
During angiogenesis, or the production of new blood vessels, SMCs maintain a proliferative state              
to allow for the growth and formation of these new vascular tissues within the body. This process                 
continues until the tissues exhibit the desired complex system seen within mature ​systems (Guo & Chen,                
2012). At this point, TGF-β binds to specific type I and type II kinase receptors present on the SMCs.                   
This activates TGF-β within the SMCs, and results in differentiation of the SMCs present within the                
15 
 system (Perrella et al., 1998). The differentiation of the SMCs slows the proliferative state and instead                
induces the normal mature contractile state (Guo & Chen, 2012). 
There have been multiple ​in vivo experiments performed in mice to determine whether genetic              
alterations of TGF-β alleles or the removal of receptors in SMCs could decrease TGF-β expression within                
the vascular system (Grainger et al., 1998; Guo & Chen, 2012). Both studies have shown a correlation                 
between decreased TGF-β expression and allele deletion or kinase receptor removal. Furthermore,            
decreased TGF-β expression has also been correlated with fewer levels of differentiation markers within              
the SMCs, increasing proliferation capacity within the system (Grainger et al., 1998; Guo & Chen, 2012).                
This diminished capacity for cellular differentiation leads to the continued proliferation of the SMCs              
within the blood vessel, which causes the formation of IH within patients. While pilot studies have shown                 
promise with genetic alterations of SMCs, the cost needed to perform these experiments pose limitations.               
On average, experimental setup can cost as much as $2,000 per experiment (NIH n.d.). Therefore, a less                 
expensive alternative should be explored.   
2.3.2 Microspheres for Growth Factor Delivery 
A second investigated solution to create the characteristic lesions of IH is through the release of                
growth factors to induce SMC proliferation. This process can be completed through the use of biomaterial                
based microspheres integrated within SMC toroids. The microspheres can encapsulate and release growth             
factor through either surface degradation or diffusion. Microspheres are known for their ability to easily               
diffuse within a variety of solvents and substances depending on the material they are comprised from.                
Through varying fabrication techniques, microspheres can be synthesized from various materials,           
including polymers, glasses, and ceramics. Due to this high variety of fabrication techniques,             
microspheres can be selected and tailored to improve functionality within their specific applications             
(Hossain et al., 2015).  
There is a vast assortment of applications for microspheres both in the field of biomedicine and in                 
other commercial applications. These applications can include separation of molecules and medical            
imaging (Ma et al., 2005; Upputuri & Pramanik, 2017). Microspheres are also commonly used as a                
scaffold for cells within biological systems. Because the spheres can be synthesized to have a porous                
architecture, they can be used for seeding cells in a mechanism allowing for the transfer of nutrients                 
(Dastidar et al., 2018). Polycaprolactone and titanium dioxide composite microspheres, for example, have             
shown to be osteoconductive, possessing pores found to adequately support the ingrowth of bone tissue               
(Khoshroo et al., 2017). 
Drug delivery systems are potentially the most widely-utilized applications of microspheres.           
Microspheres with intended drug delivery applications are typically loaded with some chemical or             
molecule drug prior to implementation within the body. The release of this drug typically occurs by some                 
form of diffusion through the matrix or by microsphere degradation (Fredenberg et al., 2011).              
Drug-releasing microspheres are used in many ways and in different organ systems. Microspheres             
wielding a neuro-protection drug, for one, can be injected into the eye, for nerve maintenance of patients                 
with eye or vision conditions such as glaucoma (Bravo-Osuna et al., 2018). Drug-eluting microspheres              
can also be used for occlusion of blood vessels that supply nutrients to liver tumors, a process known as                   
16 
 chemoembolization (Fuchs et al., 2017). Pulmonary drug delivery is another common microsphere            
function, for which the microscopic inhalants bind to lung tissue prior to bloodstream re-absorbance              
(Deshmukh & Sangawar, 2016). 
2.4 Microsphere Fabrication  
Microspheres can be synthesized through multiple techniques (Table I). Most microsphere           
fabrication techniques exploit the phenomenon of emulsion, though some others use more complex             
microfluidic systems for a more precise, monodisperse end product (Geczy et al., 2018). The simplest               
emulsion techniques are known as single emulsions where a solution of the dissolved matrix material is                
added to a solution of very low affinity. For instance, if the matrix material is dispersed in water, the                   
solution could be added to a hydrophobic substance, such as oil. The solutions are then disrupted through                 
stirring, forming small orbs of the matrix solution. A drug can be incorporated into the microspheres                
either directly into the aqueous matrix solution prior to the emulsion or after the microspheres have been                 
formed and isolated from the emulsion. If the drug and matrix material have opposing affinities to water,                 
this emulsion process is repeated, resulting in a double emulsion (McCall & Sirianni, 2013). 
Another similar microsphere fabrication technique, known as the polymerization technique,          
involves dispersing droplets of monomers of matrix material into a different solution. When heat is               
applied during fabrication, the monomers begin to polymerize. This process often involves incorporation             
of crosslinkers, stabilizers and a reaction catalyst (Alagusundaram, 2009; Wang et al., 2006). Though this               
is typically a fast fabrication process, the incorporation of many reagents can increase sensitivity to               
reaction conditions (Dastidar et al., 2018). 
Spray-drying is another common fabrication method used in laboratory settings. For this            
technique, the drug and matrix material are dissolved in some volatile solvent, which quickly evaporates               
upon heating. After evaporation of this solvent, the matrix and drug form mist droplets which can be                 
isolated from the air with cyclone separating equipment. This fabrication is most appropriate for              
applications involved with pathogens (Alagusundaram, 2009). Unfortunately, with this process,          
controlling microsphere attributes, such as pore-size, is very difficult and this technique cannot be used               
with heat-sensitive materials (Dastidar et al., 2018). 
The phase-separating method for microsphere fabrication begins with a solution of dissolved drug             
and dispersed droplets of the matrix material. A substance of very low affinity to the solvent is then added                   
to the solution, triggering the incorporation of the drug into the matrix droplets in the form of a visible                   
liquid-to-solid phase change (Alagusundaram, 2009; Guo et al., 2015). This process can be used to form                
unique microsphere structures such as, core-shell copolymer formations (Guo et al., 2015). In this              
process, however, uniform droplet-drug dispersion is difficult to achieve and there is high sensitivity to               
reaction conditions (Dastidar et al., 2018). 
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 Table I:​ Common Microsphere Fabrication Techniques  
 
 
2.5 Potential Biomaterials for Microsphere Fabrication 
The material of which microspheres are synthesized usually depends on the intended application.             
Though microspheres can be fabricated from a variety of material types, those used in the medical field                 
are most commonly made of ceramics, glasses, and polymers (Table II). Materials from each of these                
classifications were considered for the growth factor delivery system and are later described in greater               
detail.  
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 Table II:​ Biomaterials Commonly Used for Microspheres 
 Glasses & Ceramics Synthetic Biomaterials Natural Biomaterials 
Advantages ● Often bioactive and can 
form strong bonds with 
biological tissues (Rahaman 
et al., 2011) 
● Often osteoconductive, 
promoting bone growth 
(Rahaman et al., 2011) 
● Antimicrobial and 
wound-repair properties 
(Kawashita, 2005; Rahaman 
et al., 2011) 
● Degradation profiles can be 
easily tailored (Sinha & 
Trehan, 2003) 
● Can be altered to exhibit 
controlled drug release 
(Sinha & Trehan, 2003)  
● Products of degradation are 
typically biocompatible (Del 
Gaudio et al., 2017) 
Disadvantages ● Usually very brittle which 
increases risk of 
fracture-related 
complications (Rahaman et 
al., 2011) 
● Degradation can yield 
harmful products (Sinha & 
Trehan, 2003) 
● Usually hydrophobic, 
making encapsulation of 
hydrophilic drugs difficult 
(Sinha & Trehan, 2003) 
● Degradation often occurs 
very quickly unless the 
materials are altered (Del 
Gaudio et al., 2017) 
● Cross-linking agents used to 
slow degradation often have 
some toxicity (Del Gaudio et 
al., 2017) 
Examples of 
Microsphere 
Applications 
● Porous glass microspheres 
to serve as chromatography 
beads (Conzone & Day, 
2009) 
● Ceramic microspheres that 
release radiation-emitting 
isotopes for cancer therapy 
(Day & Ehrhardt, 1988) 
● Hydrolyzable microspheres 
for controlled drug release 
with degradation tailored to 
application via processing 
alterations (Anderson & 
Shive, 1997) 
● Embolization microspheres 
for blocking blood flow to 
tumors (Saralidze et al., 
2010) 
● Gelatin microspheres for 
delivering anticancer agents 
to the stomach (Hashida et 
al., 1977) 
● Targeted drug delivery using 
polymers that degrade in 
specific body regions such 
as chitosan that degrades in 
response to a colon bacteria 
(Lorenzo-Lamosa et al., 
1977)  
Common 
Materials 
● Silicon dioxide, Aluminum 
oxide, Iron oxide, 
Hydroxyapatite, Yttrium 
oxide, & Yttrium phosphate 
(Kawashita, 2005) 
●  Polyesters, such as 
polylactic acid (PLA) and 
poly(lactic co-glycolic) acid 
(PLGA) (Anderson & 
Shive, 1997) 
● Gelatin, Albumin, Starch, 
Silk, & Chitosan 
(Alagusundaram, 2009) 
 
2.5.1 Gelatin  
Collagen, one of the most abundant proteins in the human body, found in the extracellular matrix                
of most mammalian cells, has a hierarchical structure in nature (Fratzl, 2003). Hydrolyzing or denaturing               
the triple helix of collagen fibers results in gelatin, one of the most commonly used biological materials in                  
many biomedical applications, including microspheres (Benjakul & Kittiphattanabawon, 2018). Gelatin is           
a promising biomaterial in that it is non-toxic, biocompatible and biodegradable, like collagen (Table II)               
(Wang et al., 2016a). Most of the characteristics of gelatin, however, vary greatly depending on extraction                
method, the degree of denaturation, electrolyte content, and other processing parameters (Olsen et al.,              
19 
 2003). Overall, gelatin is quite weak in terms of its mechanical strength, and it is quickly hydrolyzed and                  
broken down in most biological systems. To increase its strength and resistance to degradation, gelatin is                
often chemically altered with crosslinking agents (Ratanavaraporn et al., 2010). The majority of these              
crosslinking agents, such as glutaraldehyde, are cytotoxic (Poursamar et al., 2016). Other non-toxic,             
less-studied crosslinkers, such as mammalian derived transglutaminase, have however, shown potential           
for gelatin stability enhancement applications (Yang et al., 2018). A major advantage of gelatin is its low                 
cost in comparison to many other microsphere scaffold materials. 
Gelatin is often used as a drug carrying biomaterial as it is capable of binding to a variety of                   
organic molecules including nucleic acids, sugars and proteins. For example, based on its isoelectric              
point, which is determined by method of denaturation, gelatin can bind to growth factors of an affinitive                 
charge (Young et al., 2005). Additionally, gelatin is bioresorbable which allows for the drug release via                
bulk degradation due to common physiological reactions such as hydrolysis. If an encapsulated protein or               
drug does not release via diffusion, active hydrolysis and proteolytic activity will expose it as the gelatin                 
degrades (Young et al., 2005). Crosslinked gelatin has thus shown a capability of carrying growth factors                
through static charge and releasing them upon degradation (Yamamoto et al., 2001). A water-in-oil              
emulsion technique is typically performed to fabricate gelatin microspheres which are later submerged in              
a solution containing the crosslinking agent (Tabata et al., 1999). Size is a difficult parameter to control                 
with gelatin microspheres due to the inability to produce consistent polymer sizes after collagen is               
denatured (Saddler & Horsey, 1987). The release profile of drug from a gelatin microsphere varies greatly                
in accordance with its molecular make-up and fabrication specifications. Gelatin’s drug elution profile             
depends on the crosslinking agent used, as crosslinkers are often found to yield a more-controlled release                
(Yang et al., 2018, Cortesi et al., 1998). Despite the amount of cross-linking, however, most gelatin                
microspheres lose a great deal of drug during burst release (Iwanaga et al., 2003). Alterations such as                 
adding methacrylic anhydrides to gelatin can also result in a more sustained drug release with exposure to                 
collagenase enzymes (Nguyen et al., 2015).  
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 Table III: ​Pros and Cons of Gelatin for use in Microspheres 
Gelatin 
Pros Cons 
Non-toxic and biocompatible 
Physical and chemical characteristics vary based 
on extraction method 
Biodegradable characteristics High potential for burst release 
Can increase strength and resistance to 
degradation through crosslinking Majority of crosslinking agents are cytotoxic 
Inexpensive Difficult to control microsphere size 
Commonly used biomaterial for drug carrying 
and drug release  
 
2.5.2 Silk  
S​ilk is a natural protein fiber that is cultivated from the ​Bombyx mori silkworm. The thread of silk                  
that is produced is composed of a structural fibroin protein and is coated by the protective sericin protein.                  
During the manufacturing process of silk fibers, sericin is removed through a degumming process as a                
waste product (Mondal 2007). The remaining silk fibroin material can be used in a wide variety of                 
applications because of its unique structure and advantageous properties, (Table IV). During the             
silk-spinning process, silk fibroin self-assembles into crystalline β-sheet structures through the           
incorporation of physical crosslinking (Hu et al., 2006) which allows the silk fiber to possess beneficial                
mechanical properties including high strength, toughness, and elasticity. Other unique properties of silk             
fibroin include biocompatibility, biodegradability, and a high stability because of its structure. Due to the               
advantageous attributes of silk fibroin, it has been investigated for use in both medical and clinical                
applications. Additionally, silk fibroin produces a very low antigenic response within the body and allows               
for cell adhesion (Wang et al., 2007). Some of the applications for this polymer include enzyme                
immobilization, surgical sutures, tissue engineering scaffolds, and drug delivery systems.  
In drug delivery applications, silk fibroin can be used to fabricate microspheres for the              
encapsulation and controlled release of proteins. There are various methods for the preparation of silk               
fibroin microspheres, such as a water-in-oil emulsion to encase proteins (Srihanam et al., 2011). For the                
fabrication of our silk microspheres, we will be following a procedure using silk/PVA blend films (Wang                
X. et al., 2010). By air-drying the blended solution, dissolving the film in water, and removing any                 
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 residual PVA through centrifugation, water-insoluble silk microspheres can be obtained. Also, silk fibroin             
microspheres have the capability to be loaded with growth factors to be used for delivery applications.                
(Wenk et al., 2009). Additionally, the material’s crystalline beta-sheet structure allows for controllable             
drug release. (Lammel et al., 2010).  
Table IV:​  Pros and Cons of Silk for use in Microspheres 
Silk 
Pros Cons 
Non-toxic Relatively expensive 
Promotes cell growth and proliferation Wide distribution of microsphere sizes 
Low antigenic response 
Degradation behavior is dependent on silk 
processing 
Can be loaded with growth factors 
 
Biocompatible 
Relatively slow degradation; zero order release 
Biodegradable 
High drug loading capacity and stability 
Minimal electrical conductivity 
 
2.5.3 Chitosan 
Like gelatin, chitosan is a natural biomaterial that is derived from a highly-structured fibrillar              
natural material found in a variety of organisms. Chitosan, a polyelectrolytic polysaccharide that is              
produced from the deacetylation of chitin, is commonly acquired from the shells of crustaceans (Hudson               
& Jenkins, 2001). Chitosan possesses many intrinsic properties that bode well for its use in biomedical                
applications (Table V). For example, chitosan is highly soluble and thus, can be used in a variety of                  
structures including gels, films, and fibers (Ridaudo, 2006). Also, chitosan is biocompatible and inert,              
thus posing little risk of immune rejection upon implantation within the body (Hao et al., 2010).                
Furthermore, chitosan has been shown to have wound-healing attributes and its oligosaccharide            
degradation products have been found to facilitate proliferation, especially among nerve cells (Kim et al.,               
2008, Zhao et al., 2017). However, due to its hydrophilic nature and its sensitivity to pH change, chitosan                  
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 is not very stable in comparison to other biomaterials (Ridaudo, 2006). To increase its stability, chitosan                
can be crosslinked with a variety of agents such as genipin and vanillic aldehyde (Kawadkar & Chauhan,                 
2012; Zhai et al., 2018). Because of its unique properties, chitosan is used in a variety of applications with                   
fields ranging from agriculture to medicine (Hudson & Jenkins, 2001).  
 Many of the biomedical applications of chitosan involve drug delivery, especially with drugs for              
regenerating tissue within the nervous system (Wang et al., 2016 b, Zhao et al., 2017). Chitosan has high                  
affinity to many proteins, which makes it a good protein-drug carrier (Hao et al., 2010). Additionally,                
chitosan is bioresorbable which allows for the release of drug via bulk degradation usually due to                
hydrolysis and enzymatic activity and a variety of modifications can be performed to adjust its rate of                 
degradation (Di Martino et al., 2005). For fabrication, chitosan microspheres are commonly created             
through the emulsification technique, for which various parameters, such as stirring speed, can be altered               
to change resulting properties (He et al., 2016). For example, chitosan microsphere drug-release             
properties can be controlled by altering particle degradation through surface modifications such as             
acetylation of amino groups (Zhou et al., 2014). Additionally, increased crosslinking of chitosan             
microspheres has been associated with prolonged release profiles (Zeng et al., 2011). The fragments of               
chitosan, formed upon degradation, and platelet derived growth factor, have even been shown to work in                
conjunction with one another to promote cell proliferation. Chitosan particles loaded with PDGF-BB, for              
example, were observed to stimulate a significant increase in cell count and viability of human gingival                
fibroblasts in comparison to treatment groups with exposure to chitosan and PDGF-BB alone (Silva et al.,                
2013).  
Table V: ​ Pros and Cons of Chitosan for use in Microspheres 
Chitosan 
Pros Cons 
Biocompatible Not very stable 
Zero foreign body response Often requires a cross-linking agent  
High affinity to most protein Sensitive to environmental conditions 
Non-toxic degradation products Usually exhibits burst release 
Chitosan oligosaccharides promote cell 
proliferation 
 
Degradation profile can be controlled by 
manipulating fabrication 
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 2.5.4 Polyanhydrides 
Polyanhydrides are a class of synthetic polymer used in many biomedical applications, possessing             
a variety of the advantageous and disadvantageous properties (Table VI). For one, polyanhydrides can be               
sterilized quite easily via gamma radiation and are considered safe for use within a variety of biological                 
systems. Further, the degradation products of polyanhydrides are entirely eliminated from the body within              
a few months, as they are often composed natural body constituents, and some serve as easily                
processed-metabolites (Kumar et al., 2002). Though these by-products are acidic, they generally do not              
lower surrounding pH to the same degree as other degradable polymers like polyesters (Gopferich &               
Langer, 1993). 
 Polyanhydrides have a variety of properties that make them suitable for advanced drug delivery              
applications. For instance, polyanhydrides are capable of carrying and stabilizing a variety of protein drug               
types such as antibodies and growth factors (Ghadi et al., 2017; Delgado-Rivera et al., 2013).               
Polyanhydride microspheres are commonly fabricated by either hot-melt encapsulation, spray drying, or            
double emulsion solvent removal, though there are ultrasonic stream disturbance techniques that can be              
employed with the proper equipment. (Kumar et al., 2002; Berkland, 2004). Polyanhydrides, unlike other              
polyesters and most biomolecules, undergo surface degradation, yielding predictable drug-release profile           
that approach zero-order release (Gopferich, 1996). This unique release profile comes from a combination              
of two characteristics: its hydrophobicity and its abundance of hydrolysable anhydride bonds on the              
material surface (Uhrich et al., 1999). These highly favorable drug release characteristics, in             
accompaniment with localization and targeting, makes polyanhydrides very suitable for applications           
involving highly toxic drugs, such as those used in cancer treatment (Jain et al., 2005). Fabrication and                 
engineering design can have an influence on the release profile of a drug. For instance, the distribution                 
and release of drug from polyanhydride microspheres have been observed to vary in size of the protein it                  
was carrying (Berkland, 2004). Polyanhydrides in general, release drugs steadily over long durations             
compared to other polymers, and these release durations can be extended via copolymerization. For              
example, microspheres composed of poly sebacic anhydride, one of the most common microsphere poly              
anhydrides, was shown to be able to release bovine serum albumin in a controlled fashion over the span of                   
close to two weeks in sodium dodecyl sulfate aqueous solution; this release duration was seen to increase                 
when copolymerized with poly(1,6-bis-​p​-carboxyphenoxy) hexane (Determan et al., 2004). 
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 Table VI: ​ Pros and Cons of Polyanhydrides for use in Microspheres 
Polyanhydrides 
Pros Cons 
Zero-order drug release Fast degradation time (less than a week) 
FDA approved for drug delivery processes 
Needs caustic chemicals to prepare microspheres 
(e.g., dichloromethane) 
Biodegradable Relatively expensive 
Breakdown products non-harmful to host 
 
A plethora of variants, each with unique properties 
Supports immune response (adjuvant) 
 
2.5.5 ​Poly(lactic-co-glycolic acid) (PLGA) 
PLGA is a polyester with many advantages for use as a biomaterial (Table VII). Comprised of                
alternating copolymeric chains of PLA and polyglycolic acid (PGA) monomers, water hydrolysis of the              
esteric bond is the common means of breaking apart chains (Danhier et al., 2016). As a bulk degrading                  
copolymer, PLGA is liable to break suddenly by water entry into its matrix. However, by varying the ratio                  
of PGA monomers to PLA monomers, different rates of sustained drug release may be attained. Rate of                 
drug release also depends on the thickness of the hydration layer surrounding the polymer (Makadia et                
al., 2011). The former monomer, lacking one methyl group which the latter contains, is relatively polar,                
so occupying polymeric chains with its presence may increase water solvation and hydrolysis. For              
example, an 85:15 PLA to PGA ratio, has been shown to have a lower burst release compared to a 50:50                    
ratio copolymer (Han et al., 2016). Moreover, lyophilized powder reagents of varying molecular weights              
adds extra control of degradation rate, where heavier chains degrade slower and exhibit less burst release                
(Makadia et al., 2011).  
Depending on the fabrication technique utilized, a narrow or wide size distribution can be              
attained. A variety of techniques exist to produce PLGA microspheres, including microfluidics, coaxial             
tri-capillary electrospraying, and emulsion techniques (Han et al., 2016). Usually, oil-in-water and            
water-in-oil-in-water emulsions do not involve complex reagents dichloromethane, which is used as a             
solvent, and other machinery (Han et al., 2016). In terms of these emulsion techniques, the former tends                 
to produce a narrow distribution of microspheres and involve less reagent than the latter (Han et al.,                 
2016). However, other variants of emulsion techniques can be used to improve the encapsulation              
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 efficiency of biologics over these more traditional emulsion methods (Han et al., 2016; Yuan et al., 2013).                 
Having a size profile that can be varied from nanoscale to microscale, PLGA microspheres can be easily                 
incorporated into vasculature without affecting native tissue architecture. However, microsphere          
diameters must be less than 200μm to avoid an immune response ​in vivo (Yi et al., 2008; Han et al.,                    
2016). As a scaffold material for blood vessels, it does not interfere with normal blood vessel function                 
until it degrades into acidic products, which can, in turn, inhibit SMC function and potentially affect the                 
function of PDGF-BB, if pH drops much below the 7.4 pH at which PDGF-BB works optimally (Yi et al.,                   
2008). In terms of cost, manufacturers provide an assortment of powdered forms of the polymer. Though                
more expensive than gelatin, large catalogs of options compensate for this shortcoming.  
Table VII: ​ Pros and Cons of PLGA for use in Microspheres 
PLGA 
Pros Cons 
Customizable degradation rates and reactivities 
based on component monomer units and identities 
Burst release may cause premature release of 
loaded drug 
FDA approved for drug delivery processes 
Requires caustic chemicals to prepare 
microspheres (e.g., dichloromethane) 
Biodegradable 
 
Breakdown products non-harmful to host 
Sustained release of loaded drugs 
Does not interfere with SMC proliferation/growth 
No immunogenic response 
 
2.5.6 Hydroxyapatite 
Synthetic hydroxyapatite is a ceramic biomaterial used in many applications such as bone             
scaffolding, bone filling, and implant coating. Among other properties (Table VIII), hydroxyapatite is             
strong and wear resistant but does not possess much toughness due to its brittle nature. Hydroxyapatite is                 
biocompatible and bioactive, which allows it to bind to biological tissues such as bone. In addition to                 
orthopedic applications, hydroxyapatite is used in drug delivery (Szczes et al., 2017).  
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  Hydroxyapatite drug delivery systems often take advantage of microsphere carriers.          
Hydroxyapatite microspheres are typically hollow or mesoporous and are thus capable of carrying large              
amounts of drug (Szczes et al., 2017). Though co-precipitation and microwave radiating techniques are              
sometimes used in their fabrication, hydroxyapatite microspheres are commonly synthesized via a simple             
hydrothermal process entailing a dropwise, stirred emulsion that is later autoclave prior to particle              
retrieval (Lin et al., 2011; Qi et al., 2015). Unfortunately, in order to control microsphere conformation                
with this method of fabrication, acidic modifiers, such as citric acid, must be incorporated, which could                
affect biocompatibility (Qi et al., 2015).  
The uniques degradation behavior of hydroxyapatite results in many favorable drug-release           
attributes. Standard, synthetic hydroxyapatite is incapable of much resorption and thus must be altered              
chemically, through the addition of ions such as magnesium or strontium, to increase degradation (Xiao et                
al., 2016). Though it cannot degrade quickly in most biological systems, hydroxyapatite is porous which               
allows for diffusive release of a loaded drug. Hydroxyapatite microspheres have been shown to exhibit               
sustained release of a variety of drugs, such as hemoglobin or vancomycin, lasting over the course of                 
several days (Qi et al., 2012; Long et al., 2013). 
Table VIII: ​Pros and Cons of Hydroxyapatite for use in Microspheres 
Hydroxyapatite 
Pros Cons 
Biocompatible Poor degradability; occurs very slowly 
Capable of cell adhesion Poor mechanical properties 
Supports binding of MSCs 
Requires caustic chemicals to prepare microspheres      
(e.g., dichloromethane) 
Relatively non-toxic Exhibits burst release 
Minimal electrical conductivity Low surface area 
Zero foreign body response Low drug loading capacity 
 
3. Project Strategy  
3.1 Initial Client Statement  
The initial client statement provided by our client, Dr. Marsha Rolle is stated as follows: 
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 “To develop a controlled release microsphere that can encapsulate and release PDGF-BB at a              
specified dose and duration, integrate within self-assembled human cell rings, maximize encapsulation            
efficiency by minimizing growth factor waste, and has the capability of being reproduced at different               
scales.” 
The initial client statement was then further expanded and revised to incorporate the determined              
constraints, objectives, and functions. 
3.2 Objectives  
After review of the client statement and constraints, a list of principle objectives were identified               
and  compiled to address the most critical aspects for the design:  
● Controlled PDGF-BB release 
● Efficient PDGF-BB encapsulation 
● Consistent microsphere size distribution 
● Significant microsphere yield via fabrication method 
● Cost of materials 
Controlled PDGF-BB release: ​The purpose of this objective is to measure the amount of              
PDGF-BB being released into the system. The microsphere should begin releasing growth factor             
at a minimum of 10 days after initial combination within the tissue ring. The release profile                
should provide a constant and controlled release to allow for ring fusion and to minimize waste of                 
growth factor. The microsphere should release approximately 50-100 ng/mL of PDGF-BB to the             
SMC tissue ring over a 1-2 week duration.  
Efficient PDGF-BB encapsulation: The purpose of this objective is to verify that the microsphere              
possesses a high encapsulation efficiency to minimize growth factor or protein waste.  
Consistent microsphere size distribution: ​To ensure precision and repeatability, another important           
objective is for the microsphere to have a maintained size distribution. The fabrication process of               
the microspheres should allow for consistent diameter measurements and uniform properties.  
High microsphere fabrication yield. ​In order to determine which material is the most effective for               
our system, the material’s fabrication method should allow for easy replication and should result              
in a high microsphere yield. 
Inexpensive microsphere design. ​The total cost for our system and the components used to              
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 maintain its function should not exceed the $900 budget for the project.  
3.2.1 Comparison of Objectives  
After meeting with the client and conducting a literature review, the objectives were evaluated              
and prioritized in terms of importance by developing a pairwise comparison chart. The pairwise              
comparison chart was used to establish new design objectives.  
Table IX:​ Pairwise Comparison for the Evaluation of Objectives 
 
In order to determine their significance relative to one another, each objective was compared and               
contrasted against one another using the pairwise comparison chart (Table IX). In this chart, a value of 1                  
or 0 signifies that an objective has greater or lesser priority to the one it is being compared to,                   
respectively. Objectives were evaluated based on their overall priority in achieving the project goals and               
satisfying the needs presented in the client statement. Through this method, the three most important               
criteria for our design were the release and encapsulation of protein. Thus, during the design               
process, these three objectives became our areas of focus. 
3.3 Constraints  
In order to successfully design our system, a list of constraints were identified and developed to                
satisfy the previously stated needs of our client. If the system did not meet each of these constraints, then                   
the project would have been determined a failure. Each constraint necessary for the success of our system                 
is listed as follows:  
The microsphere must retain PDGF-BB activity. ​While PDGF-BB is loaded within the microsphere and              
during its release into the tissue ring, through either diffusion or surface degradation, the material must                
not inhibit the function or disrupt the activity of PDGF-BB.  
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 The microsphere must be biocompatible with SMCs. ​The initial microsphere material and any additional              
byproducts produced through diffusion or degradation must be biocompatible with the SMCs. The system              
should also be non-toxic to ensure cell viability. 
The selected material must have the capability to be sterilized. ​The selected biomaterial chosen for the                
design process must be capable of being sterilized to prevent contamination.  
3.4 Functions  
After evaluation of the objectives and constraints, a list of functions were created to define each                
action the drug delivery system must perform in order to meet each of the design requirements. The                 
principle functions and the means to test them are as follows: 
Table X:​ Functions and Means of Design Requirements  
Function Mean 1 Mean 2 
Release duration for 10-14 days Selection of biomaterial with the 
most suitable properties 
Method of microparticle fabrication 
Measure cell viability Cytotoxicity assay & Live/Dead 
staining  
Observing cell viability via 
microscopy 
Measure sustained release of 
PDGF-BB 
Quantifying the material’s 
encapsulation efficiency of 
lysozyme 
Quantifying amount of lysozyme 
released over time using a release 
assay 
Minimize burst release of 
PDGF-BB 
Increasing strength and resistance of 
polymer through cross-linking. 
Adjustment of fabrication protocol 
for individual material 
Material sterilization to prevent 
contamination 
Sterilization via autoclave to kill off 
microorganisms 
UV Sterilization to prevent spread 
and growth of microorganisms 
Maintain cells at physiological 
conditions 
Ensuring cell growth with 
specialized cell culture medium 
(10% FBS, 1% Penicillin 
Streptomycin, 1% Glutamax) 
Incubation of cells in optimal 
growth conditions (37℃, 5% CO​2​, 
20% O​2​) 
 
30 
  
As seen in Table X, the first function that this design should have is a release profile for a                   
duration of 10-14 days. The means to how this function will be obtained is through the selection of the                   
biomaterial with the most optimal properties and its fabrication method to ensure prolonged release of the                
PDGF-BB to induce cell proliferation. The next function for our design is to measure the sustained release                 
of the growth factor in the system. The means for this function is through the use of encapsulation and                   
release assays, which will allow our project team to both measure and observe the release profile. To                 
prevent waste factor from being a significant issue, a function was determined to minimize the burst                
release of PDGF-BB. The means to attain this function was based on the fabrication method for the                 
biomaterial of interest, which could be accomplished through the addition of cross-linking for certain              
materials, or a combination of multiple materials within one microsphere. Another important function is              
to prevent contamination from occurring in our system. To achieve this, all relevant equipment will be                
UV sterilized before and after use. Lastly, in order to ensure cell survival in the system, a determined                  
function was for the system to maintain cells at their physiological conditions. The means to attain this                 
function will be standard cell culture procedure which will be conducted throughout the experiment. For               
incubation, the cells will be maintained at a temperature of 37℃, a CO​2 level of 5-10%, and an oxygen                   
level that is approximately 20%. 
3.5 Standards  
In order for the creation of a safe and reliable product, there are multiple industry standards which                 
will need to be met. Standards set forth by both the International Standards Organization (ISO) and the                 
American Society for Testing and Materials (ASTM) will need to be met for our project to be successful. 
The first industry standard that needs to be met for our project is ISO 10993-5:2009 which tests                 
for ​in vitro cytotoxicity, and encompasses our objective to produce microspheres which are biocompatible              
within the TEBV. This test ensures that the integrated microsphere surface, or byproducts released              
through diffusion or degradation, will not kill nor harm the cells in unintended ways due to toxicity from                  
these agents. Additionally, the second standard ASTM F2739-16 also encompasses our objective to             
produce biocompatible microspheres. This standard tests the quantification of cell viability within            
biomaterial scaffolds, which will also indicate that the microspheres are not harmful to the cells in                
contact. The third standard is ISO 11737-2:2009, which involves tests on the sterilization ability of               
medical devices. This ensures that the microsphere materials have the ability to be sterilized through an                
accepted procedure before being added to the TEBV, and will not cause any unwarranted harm to the                 
cells. The fourth standard which relates to our project is ASTM F3142-16, which standardizes the               
evaluation of biomolecule release from a tissue engineered medical product. This correlates with one of               
our primary objectives detailing a controlled release of PDGF-BB from the microsphere into the TEBV.               
This is focused primarily on the elimination of an initial burst release of growth factor from the                 
microsphere.   
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 3.6 Revised Client Statement  
Following further revisions and an improved understanding of the project’s constraints and             
objectives, the initial client statement was improved upon. The resulting client statement reads as              
follows: 
Design and fabricate a microsphere drug delivery system to facilitate or promote proliferation             
within a tissue engineered SMC ring, such as to mimic a lesion of intimal hyperplasia. PDGF-BB should                 
be encapsulated efficiently within the microspheres and have a controlled release from the microspheres              
to the surrounding SMCs. The microsphere design should have a 10-14 day release profile. Incorporation               
of the microspheres should not alter the integrity or conformation of the tissue ring. Effective fabrication                
and implementation of the microspheres should be reproducible.  
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 4. Design Process 
4.1 Design Selection  
As the team has elected to use microspheres in the design of an ​in vitro ​IH model, different                  
materials were compared to our baseline material of gelatin on how well each meets outlined objectives                
and constraints. Gelatin was selected as the baseline material because the Rolle lab has incorporated               
gelatin microspheres within TEBVs in the past (Strobel et al., 2017). The lowest ranked materials were                
then eliminated from further experimentation to conserve time and funds and narrow the team’s focus.  
Due to the limitation presented by the project budget and the expense of PDGF-BB cost, a                
cheaper analog protein was required for microsphere loading. For this purpose, the protein lysozyme was               
used. Lysozyme presents a similar weight and structure compared to PDGF-BB. Additionally, protein             
activity could be verified during release through the use of lysozyme specific enzyme assays.  
Each material was characterized through review of studies detailing each material’s physical            
properties, cost, fabrication method, and chemical structure. Before consideration of how well each             
material meets the team’s objectives, each material was evaluated on whether it addressed all of our                
design constraints:  
● The microspheres must retain protein activity.  
● The microspheres must be biocompatible with SMCs. 
● The microspheres must have the capability of being sterilized.  
All materials that were determined to have met all design constraints were then compared based               
on how well each material met our design objectives. Table XI shows the decision matrix comparing each                 
material.  
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   ​ ​Table XI:​ Decision matrix of microsphere materials 
 
The leftmost column lists ordered microsphere characteristics in which each material was            
compared on how well they perform in a specific category, compared to the baseline material of gelatin.                 
A rank of 1 denotes superior performance to baseline, a -1 shows inferior performance, and a 0 signifies                  
no gain or loss over using the baseline material. Shown in parentheses, each weighted value was assigned                 
based on how important that category is for attaining the overall goals of our design, as determined by                  
Table XI. The lower the weight value, the less imperative that the objective must be met.  
Assigned the lowest weight value of 1, size distribution of fabricated microspheres is deemed               
least critical as microspheres are seeded into TEBV cultures as the SMCs proliferate and form the                
component blood vessel tissue rings (Strobel et al., 2017). As the client seeks a reproducible process that                 
can make consistently sized microspheres, to enhance the standardization of the IH drug testing model,               
the microspheres must have a narrow size distribution to ensure accurate dispensing of loaded drugs, such                
as PDGF-BB, into the cell culture. If microspheres varied in size greatly, there will be unequal loading                 
and unloading of drug particles from microspheres to different regions of the vessel and negatively impact                
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 the specific targeting of an IH lesion (Strobel et al., 2017). However, microspheres will vary in size from                  
batch to batch with team fabrication protocols, so this objective is an ideal goal, and not very attainable in                   
our design, and thus not important. Among the materials selected, PLGA, polyanhydrides, and silk were               
found to have more consistent size ranges after their respective fabrication processes than the current               
process the client uses for gelatin microspheres (Berkland, 2004; ​Han et al., 2016; ​Strobel et al., 2017;                 
Wang X. et al., 2010) .  
Fabrication ease and cost, which also have lower weight values, concern the production process              
of turning each material into microspheres. Ultimately, the team wants to ascertain a cost effective               
process that can be scaled-up as desired. As such, a fabrication protocol that uses the most inexpensive                 
reagents and equipment would prove ideal for achieving this goal, but falls under the importance granted                
for size distribution. For the production of PLGA, polyanhydride, and hydroxyapatite microspheres, it             
was found that production was more lengthy and costly for each material compared to the baseline,                
whereas silk microspheres had a shorter production time and less expensive reagents used to make               
microspheres (Berkland, 2004; ​Han et al., 2016; ​Strobel et al., 2017; Wang X. et al., 2010; Xiao et al.,                   
2016) .  
Integration of the microsphere, which has a mid-range weighted value, is defined as how well it                
can fit into TEBV rings without impacting tissue structure and growth, based on microsphere size alone.                
Between 20 µm and 40 µm is an ideal range. As the final IH testing design seeks to model ​in vivo ​blood                      
vessels for accurate drug testing, to best emulate blood vessel structure, TEBV structure must be similar                
to the natural equivalent. Consequently, microspheres should not impede proper blood vessel formation             
and affect vessel properties, such as contractility (Strobel et al., 2017). Small microspheres are therefore               
favorable, and the smaller the microspheres that can be attained, the better the blood vessel structure can                 
be maintained. However, as integration/size of the microsphere is a broad category, with a range of                
permissible sizes, more flexibility in this category allows for differently sized microspheres.  
With the next two categories of higher importance, materials were compared based on the              
encapsulation and release abilities of PDGF-BB. For the first category, the materials were compared              
based on whether each could entrap the growth factor or a similarly sized protein. Every material in the                  
above matrix could support encapsulation of PDGF-BB or a protein of similar weight, such as the                
surrogate protein lysozyme. In terms of the release profile of the loaded protein, the microsphere should                
begin the sustained release of 50-100 ng/mL of PDGF-BB at minimum 10 days after fusion within a SMC                  
ring, up to 2 weeks. As the time span of release is over days, there is room for materials to exhibit slightly                      
different release profiles and rates within that time, but any candidate material should remain close to the                 
aforementioned ranges. Moreover, having a high initial burst release of the protein can prove toxic to the                 
TEBV tissue (Huang & Brazel, 2001). Compared to gelatin, PLGA and polyanhydrides support more              
sustained release into the surrounding tissue.  
The most important category is whether a material can facilitate proliferation of SMCs within the               
TEBV culture and formation of the IH lesion. Though PDGF-BB will trigger IH formation, the ability of                 
the microsphere material itself to support proliferation of cells could prove an asset for the our design,                 
which is why this category is ranked highest. The stimulation of IH within a TEBV is the ultimate goal of                    
this project, so any contribution from the microsphere material in this regard is a worthwhile feature of a                  
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 prospective microsphere material. Among all materials, only chitosan has demonstrated the ability to             
encourage cellular proliferation  (Kim et al., 2008).  
After evaluation of each material, the first and second ranked materials were selected for              
experimental study as this project’s duration of 1 academic year and limited budget of $900 prevents                
study of all materials. PLGA shows most promise in meeting design objectives whereas silk and chitosan                
show equal rank in meeting objectives. Thus, all three materials will be used in addition to the baseline,                  
gelatin. Polyanhydride and hydroxyapatite were excluded from our experiments as a result of their lower               
ranking, with fabrication cost and fabrication ease of each material the largest reasons for their rejection.                
As this project is concerned with developing microspheres capable of releasing growth factor, these              
materials’ low rankings would impede this main goal.  
4.2 Alternative Designs  
With the selection of PLGA, silk, chitosan, and gelatin as our experimental microsphere             
materials. The team first worked to optimize the production of each material. Microspheres of each               
material were fabricated from protocols that combined design steps from other published fabrication             
methods and adaptations due to available equipment.  
4.2.1 Gelatin Microspheres 
Fabrication 
Gelatin microspheres were fabricated using a water-in-oil emulsion technique (Figure 3). The            
procedure followed an adapted protocol outlined in Tabata et al. 1999. Genipin was used as a crosslinking                 
agent to strengthen the microspheres and offer more resistance to their degradation. The gelatin              
microspheres were first formed through the emulsion technique, followed by genipin crosslinking and             
loading of the microspheres with lysozyme as our test protein. The stepwise protocol for experimentation               
can be found in Appendix B. In summary, a solution consisting of 11.1% (w/v) gelatin in deionized water                  
was added dropwise to 250 mL of olive oil. Following the dropwise addition, the mixture was stirred at                  
45℃ for 10 minutes. The temperature was then lowered to 20℃ and stirred for thirty additional minutes.                 
The mixture was stirred at 800 rpm using a stir plate and stir bar. One hundres mL of chilled acetone was                     
added to the solution and stirred for another hour. An additional 100 mL of chilled acetone was added to                   
the solution and stirring continued for another 5 minutes. Microspheres were then filtered out of the                
water, oil, and acetone solution through the use of a Buchner funnel and filter paper. The microspheres                 
were washed with acetone and air dried before proceeding with crosslinking. The dried microspheres              
were added to an aqueous solution of 5 mL 1% genipin in deionized water at varying times to promote                   
different crosslinking percentages. For the initial trials, the time remained constant at 12 hours, before the                
microspheres were then collected, washed with deionized water and stored at 4℃. Microspheres that were               
used for experimental testing were UV sterilized for 10 min before being loaded with lysozyme. The                
sterile microspheres were soaked in a solution of 80 ng/µL lysozyme and phosphate buffered saline               
(PBS). The solution was vortexed and kept at 4℃ for 15 hours.  
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Figure 3: ​Schematic of gelatin microsphere fabrication process 
Observations 
Following fabrication of the microspheres, it was determined that alterations were necessary to             
increase the efficiency and reproducibility of the protocol. The most apparent limitation when performing              
this procedure was the large range of microsphere sizes. After filtration, by just viewing the microspheres                
with a naked eye, large differences in size range between the individual microspheres formed were               
observed. In an effort to limit this range, a homogenizer was used in place of stirring in an effort to                    
decrease the overall size of the fabricated microspheres. The resulting microspheres also experienced             
severe clumping during filtration, with a large aggregate of microspheres being formed within the middle               
of the plate. The aggregation could be caused by the large size of the microspheres, and therefore could be                   
eliminated through use of the homogenizer. 
In addition, a second limitation of the referenced protocol was the time to complete the               
fabrication process. Using this procedure, the fabrication took at least two days to complete due to the                 
crosslinking and loading of the microspheres. Also, the large volumes of materials being used increased               
the amount of time needed to filter the microspheres. Due to the viscosity of the oil presented within the                   
emulsion, the length of time needed for complete filtration through the filter paper and Buchner funnel                
was at least an additional hour. The procedure was altered by lowering the starting volume used for the                  
fabrication process. Instead of 250 mL, only 100 mL of olive oil was used going forward, with less gelatin                   
and genipin being used as well.  
A third limitation to the aforementioned protocol was found during the air drying step. After the                
washing step was completed, the gelatin microspheres were air dried overnight in order to evaporate off                
any remaining liquid from the surfaces of the microspheres. However, after air drying the microspheres               
had shrunk and looked as if they had denatured overnight. 
The referenced protocol was altered based on the limitations presented above. In addition to using               
smaller volumes of materials for fabrication, a homogenizer was incorporated into the stirring steps in an                
effort to limit the large size and large size distribution of the gelatin microspheres. For the final ten                  
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 minutes of the stirring step, the mixture was taken off of the plate and instead homogenized at 14,000 rpm                   
for ten minutes.  
 
Figure 4: ​Gelatin microspheres observed macroscopically following the use of the homogenizer 
In an effort to limit the time taken to fabricate the microspheres, the washing step was changed as                  
well. Instead of using a Buchner funnel and filter paper, the oil and microsphere mixture was centrifuged                 
at 7,000 rpm for five minutes or until a gelatin microsphere pellet formed. The oil was then aspirated from                   
the conical tube, and acetone was added back into the conical tube. This procedure was repeated until all                  
the oil had been aspirated out of the gelatin mixture.  
4.2.2 Chitosan Microspheres 
Fabrication 
Chitosan microspheres were fabricated using a water-in-oil emulsion technique (Figure 5).           
Genipin was used as a crosslinking agent. Similar to the gelatin microspheres, the chitosan microspheres               
were loaded with lysozyme, though for the chitosan fabrication procedure, the lysozyme was added to the                
aqueous chitosan solution prior to emulsion.  
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Figure 5:​ Schematic of chitosan microsphere fabrication process 
The procedure was adapted from a previously outlined protocol (Appendix C)           
(Karnchanajindanun et al., 2011). Generally, dehydrated chitosan was dissolved in 2% acetic acid to make               
a 0.5% (w/v) aqueous solution. Genipin was added to the solution, resulting in a 20:1 chitosan-to-genipin                
ratio. After gentle stirring to allow for cross linking, the lysozyme is added and dispersed into the                 
solution. The aqueous phase is added dropwise to a large volume (approximately 150 mL) of olive oil and                  
agitated with a homogenizer at 1,100 rpm for an hour in order to form microspheres (Figure 5). The                  
emulsion is then transferred to tubes and centrifuged to separate excess oil from the chitosan, which forms                 
a pellet at the bottom of the tube. The remainder of the liquid is removed via filtration followed by a rinse                     
with isopropyl alcohol. The microspheres were stored in 4°C and UV sterilized prior to use with cells. 
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Figure 6: ​Droplets of chitosan-genipin solution in oil prior to stirring. Red arrows point to aqueous 
chitosan-genipin droplets within the oil. 
Observations 
The procedure was altered after initial attempts, to try to improve the efficiency of the protocol.                
The most apparent drawback of the fabrication of chitosan microspheres is the duration of the process. In                 
addition to a six-hour cross-linking period, the high viscosity of the oil makes the use of a Buchner funnel                   
for filtration quite tedious. The olive oil emulsion volume was therefore reduced by half and               
centrifugation was performed to remove most of the oil prior to the filtration step. After drying onto filter                  
paper over the funnel, the chitosan spheres clumped together forming flakes. The observed clumping was               
not however as severe as that observed with the gelatin microspheres.  
4.2.3 Silk Microspheres  
Fabrication 
The team prepared silk microspheres by adapting a silk/PVA blend film procedure (Figure 7)              
(Wang X. et al., 2010). The full stepwise protocol can be found in Appendix D. In this process, solutions                   
of silk and PVA were mixed together at a 1:4 ratio in a glass beaker. The blend solution was transferred to                     
a 35 mm petri dish and stirred at 150 rpm for 2 hours at room temperature. Afterward, the blend solution                    
was left in a fume hood to dry overnight and form a dried film. To dissolve the blend film, 10 mL of                      
Milli-Q water was added to the petri dish and shaken gently for 10 minutes at room temperature. The                  
mixture was transferred to a centrifuge tube and centrifuged at 4,000 rpm for 20 minutes, and the                 
supernatant was then carefully removed. This process was repeated twice. The adhered pellet was              
suspended in 2 mL of Milli-Q water. A vortex device was used to disperse the clustered silk microspheres                  
for 15 seconds. For storage, the suspended microspheres were placed at 4℃.  
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Figure 7:​Schematic of silk microsphere fabrication process 
Observations 
Several adjustments were made to the silk microsphere fabrication protocol in order to improve              
the efficiency of the technique and consistency of the results. One limitation in this procedure was the                 
dispersion of the microspheres. To produce the actual particles after centrifugation, a vortex was used for                
the disruption of the clustered microspheres. Vortexing had caused the silk/PVA mixture to appear cloudy               
in its suspension which allowed for the determination of the presence of microspheres (Figure 8).  
 
 
Figure 8: ​Dispersed silk microspheres in suspensio​n 
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 The vortexing time for the silk/PVA mixture was therefore reduced from the 15 seconds stated in                
the protocol. Another limitation was the filtration of the silk microspheres. Initially, the silk microspheres               
were filtered using a Buchner funnel and filter paper for observation via microscopy. However, the               
microspheres would adhere to the fibers of the filter paper which made it difficult for observation. To                 
address this issue, the suspended silk solution was vortexed and then transferred to a petri dish to obtain                  
phase contrast images (Figure 9).  
 
Figure 9:​ Phase Contrast image of Silk Microspheres (40x) 
In this image, a nearly uniform silk microsphere particle distribution can be observed. This image               
demonstrates that this fabrication procedure is capable of generating microspheres with a relatively             
consistent size distribution.  
4.2.4 PLGA Microspheres  
Fabrication 
PLGA microspheres were made by a water-in-oil-in-water emulsion protocol synthesized from           
different studies (He et al., 2011; Koda et al., 2017; Nafissi et al., 2011; Li et al., 2014). The full stepwise                     
protocol can be found in Appendix E. All steps were performed in a fume hood, except for the                  
centrifugation step (Figure 10). First, a lysozyme solution was prepared and mixed with a PLGA solution                
to make a 10% oil solution. The resulting mixture was then sonicated with the Misosonix Sonicator                
XL2000 for 30 seconds. This mixture was then added to a 300 mL 10​°C ​1.0% (w/v) PVA bath ​and                   
homogenized at ~11,250 rpm for about 30 seconds. The solution was then spun at 500 rpm for 3 hours at                    
room temperature. The microspheres were collected by filtering the 300 mL PVA solution through 60 mm                
filter paper and washing with isopropanol three times, and prior to centrifugation at 5000 rpm for 30                 
minutes. As freeze-drying could not be performed immediately, for temporary storage, the sample was              
stored at -20℃. 
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Figure 10:​ Schematic of PLGA microsphere fabrication process 
Observations 
The original PLGA microsphere protocol was altered to enhance yield and accommodate            
available equipment. The homogenizer used for the protocol seemed to generate heat when ran for about 1                 
minute, so the homogenization time was lessened to 30 seconds. Moreover, as the microspheres were               
suspended in a 300 mL PVA solution, centrifugation proved difficult, so the bath was filtered through 60                 
mm filter paper three times with a isopropyl alcohol wash instead. The resulting volume of sample                
collected was 7 mL, which was centrifuged for 30 minutes at 5000 rpm to see if centrifugation could                  
work. A white pellet was collected. About 2 mL of the sample was pipetted into a petri dish and observed                    
under a phase contrast microscope (Figure 11) . 
 
 
43 
  
Figure 11:​ PLGA microspheres in isopropanol (20x). The green arrows point to clumps of dried 
microspheres.  
PLGA microspheres can be discerned as individual clear specks, but most appear clumped             
together in black masses of individual microspheres (Figure 11). Moreover, when observing the             
microspheres under the microscope, as the plate was tilted, PLGA microsphere clumps could be collected               
onto the plate.  
 
5. Design Verification  
5.1 Flow of Methodology 
Following the fabrication of the four alternative microsphere types, it was necessary to establish              
and run multiple experiments in an effort to alter and eliminate the alternative designs until an exceptional                 
final microsphere design has been reached. The final microsphere design must incorporate all design              
objectives, functions, means, and constraints in order to establish a safe and reproducible microsphere              
which meets our design goals. Therefore, a methodology flowchart was established to organize the              
experiments run throughout the entirety of the project (Figure 12).  
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Figure 12:​ Methodology flowchart of alternative design testing 
Experimental testing was broken down into two separate phases: Test Microspheres (I) and Test              
Microspheres (II). The reasoning for the distinction between these experiments was based on the ease of                
the procedures, as well as the duration of each experiment. Phase I consisted of microscopy testing using                 
Scanning Electron Microscopy (SEM), and a MTT assay to investigate biocompatibility. Phase I testing              
could be performed without protein loading included in the fabrication process, since these experiments              
investigated physical properties of the microsphere material solely.  
Microspheres were first imaged through the use of an SEM to determine microsphere shape,              
structure and mean size and distribution. For the purposes of our goal, the microspheres would need to                 
maintain a reproducible size range between 20 and 40 µm to be considered successful. Biocompatibility               
testing was conducted to ensure that none of the material designs present a cytotoxic risk to the cells                  
during implantation and degradation. The results of the Phase I tests were used to eliminate some of the                  
alternative design materials.  
Phase II testing of the microspheres consisted of both a protein encapsulation assay and a release                
assay. These assays were separated from the previous Phase I methods because incorporation of a protein                
was required for both experimentation and integration with the selected design materials. Additionally, it              
was desirable to eliminate potential microsphere designs to minimize waste of the protein and other               
associated reagents. The encapsulation efficiency of the four microspheres was tested to determine which              
design is most the successful for entrapping a loaded protein. This is important as a required amount of                  
50-100 ng/mL PDGF-BB will need to be released to the tissue rings to stimulate proliferation of the                 
SMCs. The protein release assay allowed for the analysis of each microsphere release profile. It is                
important that the microspheres do not elicit a burst release, meaning they should not release a large                 
percentage of their loaded protein at early points in the experiments. Ideally, the microspheres would not                
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 begin releasing growth factor until 7 days after incorporation within the SMC toroid rings. Additionally,               
the activity of the releasing protein will also need to be measured during the duration of the release. It is                    
necessary that none of the materials decrease the activity or effectiveness of the cytokine during its                
release into the SMC environment.  
5.2 Phase I Testing 
5.2.1 MTT Assay 
Biocompatibility of the four chosen materials was assessed through the use of the MTT assay.               
The MTT assay is used to measure metabolic activity of the SMCs as a metric of cellular proliferation.                  
For this experiment, we measured the metabolic activity of six different experimental groups to determine               
biocompatibility. Conditioned media from gelatin, chitosan, silk, and PLGA were added to individual             
wells containing 50,000 SMCs. Additionally, a positive control group with only the 50,000 cells and a                
negative control group with no cells were included. The 50,000 cells were chosen following the               
completion of a standard curve, with cell densities ranging from 5,000 to 150,000 cells/mL. The assay                
allowed for the comparison of metabolic activity between isolated ​in vitro cells and cells in contact with                 
microspheres. The protocol for the MTT assay was adapted from the ​Cayman Chemical MTT Cell               
Proliferation Assay Kit Booklet ​(Appendix F). The absorbance readings used for data analysis were              
measured using a spectrophotometer plate reader at 570 nm.  
The six experimental groups were set up through seeding 50,000 cells/mL in 100 µL of normal                
rSMC media and incubated for one hour at 37℃ and 5% CO​2​. Microsphere conditioned media was                
prepared by adding 3 mg of the respective microspheres in 1 mL of SMC media. The media was                  
incubated at 37℃ and 5% CO​2 ​for one hour as well. Normal SMC media was aspirated from four sets of                    
wells within the 96 well plate, and 100 µL of the microsphere-conditioned media was added to the                 
respective experimental groups in the 96 well plate. This allowed for the cells to adhere to the bottom of                   
the plate prior to the addition of the microsphere media. Following the addition of reagents, the conditions                 
were measured using a spectrophotometer at 570 nm (Figure 13). 
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Figure 13:​ MTT assay for quantifying metabolic activity and biocompatibility of gelatin, chitosan, PLGA, 
and silk microspheres. Error bars represent standard deviation with N=3 and n=9. * denotes statistically 
significant decrease in metabolic activity between the microsphere material and the positive control 
group (p<0.05). ** denotes a statistically significant difference between the microsphere material and the 
control group, as well as a significant difference between those two types of materials (p<0.05).  
The average absorbance levels were calculated for each microsphere condition to allow for             
statistical comparison between the experimental groups and the control. Statistical analysis was performed             
through a Single Factor ANOVA and post hoc Tukey-Kramer test for significance.  
The Single Factor ANOVA suggested that there was a significant difference across the             
experimental groups. Therefore, the Tukey-Kramer post hoc test for significance was performed to clarify              
which experimental groups showed significant difference from the rest. The test showed that all              
microsphere conditions had a significant decrease when compared back to the baseline control.             
Additionally, chitosan had a significantly greater mean absorbance level when compared to silk. While              
the statistical tests did show a significant decrease in absorbance levels across all microsphere samples,               
the MTT assay still showed that a large amount of cells did stay metabolically active when exposed to                  
each microsphere material. The presence of metabolic activity across each sample was expected since              
each material used is classified as biocompatible according to the literature.  
 
5.2.2 Scanning Electron Microscopy  
 
SEM was used to characterize the sizes and surfaces of the microspheres. This microscopy              
method was selected because SEM allows for great resolution, depth, and a 3D perspective of materials.                
These qualities would allow us to characterize the microspheres not only by size but also by conformation                 
and surface morphology. Each material was suspended in water and stirred or vortexed. Then, 100 ​μ​L of                 
each material solution was transferred directly to conductive tape on a mounted SEM slide for analysis                
47 
 after overnight drying of the solvent from each mount (Figure 14). Average diameters of viewed               
microspheres of each material in each sample were also measured (Table XII).  
 
Figure 14:​  SEM images of prepared silk microspheres at 3600x, chitosan microsphere at 610x, PLGA 
microsphere at 635x, gelatin microsphere at 6450x.  
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 Table XII:​ Average (Avg) diameter of observable microspheres in SEM images with standard deviation 
(stdev). All lengths are in ​μ ​m.  
Microsphere Type Silk Chitosan Gelatin PLGA 
Microspheres 
Counted 
79 4 1 3 
Avg Dia​±SD (μm) 3.97​±1.95 290.03​±49.35 11.0​±0.00 108.81​±19.69 
From these images and measurements, the general size and structure of the four microsphere              
types can be compared. Among all the microspheres observed, silk gave the greatest abundance of               
viewable microspheres during image collection, with a sample size of 79 microspheres. Moreover, gelatin              
and PLGA appeared to be the largest in size with average diameters of 290.03 ​μ​m and 108.81 ​μ​m,                  
respectively. The one sphere-like structure observed from gelatin had a diameter of about 11 ​μ​m. Silk                
microspheres were generally the smallest with an average diameter of 3.97 ​μ​m but had a range of                 
diameters from 1​μ​m to 10​μ​m (Figure 15). 
              
Figure 15:​ Histogram of measured silk microsphere diameters.  
Though silk reported the lowest standard deviation, its higher sample size could have lowered               
that value. This is in contrast to the higher standard deviation values reported for the other materials due                  
to the other microspheres having smaller sample sizes. Gelatin produced virtually no microspheres that              
could be viewed, aside from a single microsphere that could be found from the SEM scope. This scarcity                  
of microspheres brings to question whether the observed gelatin particle is a microsphere or some other                
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 impurity, as there were no other spheres for comparison. Chitosan particles were clearly present but were                
not as visibly spherical as silk and PLGA, but rather appearing oblong in conformation. PLGA, among all                 
the materials, shows the most spherical structure, with pores indicating where water was incorporated into               
the spheres during fabrication. Silk gave a range of globular shapes, generally quite spherical with a                
smooth surface appearance. Additional SEM images of samples can be found in Appendix G.  
5.2.3 Phase I Conclusions  
Based on the SEM imaging of microspheres and consideration of fabrication time and ease,              
gelatin and PLGA were eliminated, even though all materials proved to be biocompatible. In addition, the                
fabrication processes for gelatin and PLGA were not ideal production factors, so they were not subjected                
to Phase II testing.  
During SEM observations, gelatin microspheres were difficult to detect. Therefore, to standardize            
SEM preparation, the same specimen mounting protocol was followed for all materials, with gelatin              
proving most difficult to break apart into individual microspheres. During all fabrication runs with the               
material, the dissolution of gelatin from a clumped state proved impossible without mechanically             
breaking it apart. Observing this lack of macroscopic and microscopic indications of gelatin microspheres,              
the material appears to have the lowest yield of microspheres among the four chosen materials. 
However, overall, there is little SEM-based confirmation of successful microsphere formation of            
gelatin microspheres, which directly counters the team objectives of finding an easily fabricated material              
that can yield microspheres. For these reasons, gelatin was eliminated from further experiments. In              
contrast, PLGA did yield microspheres that were observable in SEM. The microspheres had the most               
visibly spherical shape among all material types, but were further outside the ideal size range of 20-40 ​μm                  
compared to gelatin.  
However, while SEM images confirmed successful production of PLGA microspheres,          
fabrication proved challenging with the material in terms of equipment required and ease of handling. A                
sonicator and fume hood are required for the production of PLGA microspheres, in addition to the                
homogenizer and centrifuge the gelatin, chitosan, and silk protocols require. The higher cost of the               
polymer itself, compared to gelatin and chitosan, negatively impacts the financial accessibility of PLGA              
compared to the other materials. Also, the purchased supply of PLGA was exhausted and continued               
testing became less feasible from a cost perspective due to budget restrictions. Additionally, the              
requirement of dichloromethane, a known carcinogen, to make PLGA microspheres adds a health risk to               
the experimenter and necessitates that the entire fabrication run be performed in a fume hood. In contrast,                 
the other materials do not use carcinogenic reagents and can be performed on the lab bench safely. Once                  
made, to truly ensure no dichloromethane remains in the PLGA microsphere sample before cell testing,               
the particles must be analyzed by chromatography or other spectroscopic methods, which places further              
economic and time burdens on the lab. Furthermore, the material’s acute sensitivity to any moisture               
necessitates an almost anhydrous environment be maintained for the material’s fabrication, which can be              
challenging, as the humidity level of the lab cannot be feasibly controlled at all times. In contrast, the                  
other materials are comprised of biopolymers that primarily degrade through enzymatic and metabolic             
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 reactions, making them more durable to ambient moisture. Given these deviations from the team’s              
objectives, PLGA was eliminated from further testing.  
An ideal design would have a simple, reliable fabrication process that achieves consistent results.              
Thus far, the silk microspheres fabrication process has proven to be simple relative to the other materials                 
and has yielded physically consistent particles, making silk the most promising candidate for achieving              
the objectives of the study. Though chitosan has much larger and fewer microspheres compared to silk, as                 
observed in SEM, the material’s relative ease of production compared to PLGA and gelatin makes it                
another possible candidate to satisfy the requirements of this project. Microsphere capable of             
encapsulating a large proportion of the total loaded protein, and can release the protein in a controlled,                 
prolonged fashion are additional facets of the design that must be tested in Phase II to further assess the                   
aptitude of silk and chitosan microspheres for achieving the design goal.  
5.3 Phase II Testing 
5.3.1 Encapsulation Assay 
Encapsulation efficiency was assessed to determine the percentage of lysozyme that the matrix             
material is able to encapsulate relative to the amount added to the particles during the loading process.                 
The procedure used to determine encapsulation efficiency consisted of two stages: dissolving the             
microspheres to release any loaded protein and quantifying the loaded protein. Because different materials              
dissolve efficiently in different solvents, both of the remaining microspheres have a unique protocol for               
freeing encapsulated protein for quantification (Table XIII). Appendix G provides more detail regarding             
preparation for encapsulation quantification. During the preparation steps, neither silk nor chitosan            
appeared to completely dissolve in solution with their recommended solvent, but broke into smaller, less               
opaque pieces. The chitosan particles were especially difficult to dissolve, likely as a result of               
crosslinking during fabrication.  
Table XIII:​ Solvents used to Dissolve Microspheres for Measuring Encapsulation Efficiency 
 
Prior to dissolving the materials that were to be tested for encapsulation, the entire loaded               
microsphere batches were weighed using an analytical balance. Over the entire course of experimentation,              
a total of 4 and 5 batches were weighed for chitosan and silk, respectively. The chitosan protocol                 
incorporated a combined material mass of 52 mg (chitosan, genipin and lysozyme) and yielded an average                
of 24.7 mg of microspheres (~48% yield of materials used in fabrication). The silk protocol, which                
incorporated 255 mg of material (silk, PVA, and lysozyme), yielded an average of 167.0 mg of                
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 microspheres (~74.2% yield of materials used in fabrication). It should be noted that both silk and                
chitosan each had one batch with a yield greater than the mass of material incorporated during fabrication,                 
which is, even under ideal fabrication conditions, impossible to achieve. One possible explanation for              
this, is that the microspheres were not completely dried prior to weighing, thus erroneously increasing the                
measured mass.  
A known mass, approximately 3mg, was extracted from each of the loaded batches of each               
material and dissolved according to the tabulated protocols. A small volume of each dissolved sample was                
tested with the an EnzChek™ Lysozyme Assay (full protocol in Appendix H) to quantify the proportion                
of the encapsulated, active lysozyme. Since the concentration of lysozyme in the assay test wells was                
known, the total mass of lysozyme in the entire loaded batch could be calculated. This quantified                
lysozyme mass encapsulated within the particles was then used to calculate encapsulation efficiency (EE)              
with the following formula. 
E 00%E = quantif ied lysozymelysozyme initially loaded × 1  
Multiple iterations of encapsulation testing were performed to optimize the preparatory protocol            
and experimental setup of the assay (progression of encapsulation assay trials with experimental             
alterations shown in Appendix K). For this experiment, dissolved samples (~2 mg) for both microsphere               
materials as well as a stock solution of lysozyme (50 μg/mL), which served as a standard, were diluted                  
1:10 and 1:4, respectively, in reaction buffer and plated in triplicate. A serial dilution was performed on                 
each of the triplicate standards, resulting in seven 1:2 dilutions sourced from the original plated dilution.                
The assay also included blank wells, containing only reaction buffer and substrate (no lysozyme nor               
microsphere solution), and negative and positive control solvent wells. Negative control solvent wells             
contained only the solvent diluted 1:10 in buffer whereas the positive control solvent wells contained               
solvent diluted 1:10 in a lysozyme buffer mixture. The final lysozyme concentration for the negative and                
positive control solvent wells were 0μg/mL and 5μg/mL, respectively.  
The final trial for testing encapsulation incorporated several experimental alterations such as (1.)             
incorporating negative and positive controls for each microsphere solvent, (2.) diluting experimental            
samples so that fluorescent readings fell within the range of accuracy of the plate reader, and (3.) adding                  
NaOH base to the acetic acid-chitosan solution to raise the solvent pH and reduce lysozyme denaturation.                
The standard curve acquired for this trial demonstrated a linear relationship between lysozyme             
concentration and absorbance, as expected. The raw data for the standards, however, plateaued at an               
absorbance of approximately 700,000, indicating enzyme saturation beyond the upper limit of the plate              
reader. Because of this, the two greatest lysozyme concentrations were excluded when making the              
standard curve (Figure 16A).  
Using the linear mathematical relationship from the standards to calculate concentration of            
lysozyme in the dissolved microsphere samples, and scaling up to calculate the mass of lysozyme present                
in the entirety of the fabricated batches, the encapsulation efficiencies for each material was calculated.               
The encapsulation efficiency of silk (12.72%) was greater than that of chitosan (0.02%). Silk, however,               
had a greater standard deviation for encapsulation among the triplicate wells (Figure 16B). 
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 The positive controls for both material solvents yielded increased lysozyme concentration in            
comparison to the respective dissolved microsphere samples and negative controls. The positive controls             
for chitosan and silk, which had been plated with a lysozyme concentration of 2.5 μg/mL, yielded                
absorbances corresponding to concentrations of 1.77μg/mL and 1.93μg/mL, respectively. This attenuation           
in readings occurred due to enzyme oversaturation from plating at too large a concentration, above that of                 
the greatest value used to establish a standard curve. Silk’s encapsulation efficiency was shown to be                
significantly greater than that of chitosan (Figure 16B). Silk microspheres exhibited significantly greater             
active lysozyme encapsulation than chitosan microspheres and blank samples (p<0.05). (Figure 16C). The             
trend of increased encapsulation for silk in comparison to chitosan corroborates results from previous trial               
assays.  
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Figure 16:​ Lysozyme activity assay for quantifying encapsulation efficiency of chitosan and silk 
microspheres. Error bars display standard deviation, with n=3. (A) Standard curve graphing the 
mathematical relationship between measured absorbance and active lysozyme concentration. (B) 
Calculated encapsulation efficiency of each microsphere material. * denotes statistically significant 
according to an unpaired t-test assuming unequal variance across chitosan and silk (α=0.05). ​.​(C) Mean 
concentration of active lysozyme calculated for each experimental and control group. Lysozyme (-) 
groups contain no enzyme with acetic acid solvent, deionized water solvent, and no solvent for chitosan, 
silk, and standards respectively. Lysozyme (+) group are identical to the lysozyme (-) groups but with 
lysozyme added at 2.5μg/mL. # denotes statistically significant according to a t-test assuming unequal 
variance across chitosan and silk (α=0.05). ▲ denotes statistically significant according to a t-test 
assuming unequal variance across silk and the blank negative control (α=0.05).  
 
5.3.2 Release Assay  
A release assay was performed based on the principle of quantifying the protein present within               
the supernatant of a solution in which the loaded microspheres are suspended. Similar to the calculation of                 
encapsulation efficiency, the lysozyme released by the microspheres was quantified using the EnzChek™             
Lysozyme Assay kit to test supernatant samples of a suspension containing microspheres at various time               
points. This test was designed to provide insight on two important characteristics of the microsphere               
degradation behavior. First, the test showed the amount of lysozyme released over an extended duration               
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 of time. Second, because the assay only quantifies the lysozyme that interacts with its substrate, the test                 
confirmed protein activity after sustained release from the microspheres. 
To conduct the release assay, a known mass of lysozyme-loaded microspheres was added to              
complete SMC media. Based on a previously outlined protocol, a small sample of the culture media was                 
immediately extracted from the suspension before use in the assay, as a sample corresponding to time                
zero (Zeng et al., 2011). To collect subsequent supernatant samples, the solution was centrifuged at 1,500                
rpm for 10 minutes before the sample was extracted. The removed supernatant was replaced with fresh                
media to ensure a consistent suspension volume. Samples were taken at various time points after the                
initial incorporation of the microspheres, and afterwards immediately stored at -20°C. Between sample             
collections, the suspension was incubated at 37°C (Appendix M).  
First, a release assay was conducted on media-suspended microsphere samples from which            
samples were collected and frozen at several time points up to 15 days after microsphere incorporation;                
however, due to a misstep during fabrication, lysozyme was mistakenly added to the silk solution after                
microsphere formation which is in disagreement with the established protocol which recommends the             
lysozyme be added to the silk prior to blending with PVA. Because of this the silk microspheres used in                   
the batch were not loaded properly with protein (corroborating raw encapsulation and release data              
displayed in Appendices K and M respectively). Therefore, it was necessary to repeat the assay with                
properly loaded microspheres. Due to a time constraint, an abbreviated, 7-day release assay was              
conducted (Figure 17). A greater quantity of lysozyme was released from the silk microspheres than from                
the chitosan microspheres, likely due to the fact that the tested silk batch was loaded according to protocol                  
and contained more encapsulated lysozyme to release. The data was displayed as total mass released from                
the particles. Though this assay only lasted a week in duration, which is shorter than the target duration of                   
release for the microspheres, both chitosan and silk microspheres still seemed to hit a plateau in terms of                  
total lysozyme released. Because the samples were diluted 1:5 prior to reading in the fluorescent plate                
reader, calculated absorbances did not approach values of oversaturation, eliminating oversaturation as a             
possible explanation for the plateaus observed. Thus, the plateaus of accumulated release likely occurred              
due to all of the encapsulated drug releasing from the chitosan early on in suspension. Additionally,                
chitosan microspheres releasing less active lysozyme than silk, and plateauing at a lower value (~30mg               
released for chitosan versus ~144mg released for silk), further supports that chitosan had less lysozyme               
encapsulation and is less capable of releasing active protein.  
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Figure 17: ​Total cumulative lysozyme released from 3mg batches of SMC culture media over 1-week. 
Error bars reflect standard deviations of triplicate samples  taken within each timepoint. 
Because the IH blood vessel model application favors microspheres with a sustained release of              
protein spanning to 10 days after microsphere incorporation, an 11-day experiment was conducted. Two              
concurrent suspensions for each material were included in the experiment resulting in two experiments              
with identical setup. Release profiles were obtained according to previously detailed protocols (Figure             
18). Both concurrent trials showed similar results, though visual distinction of the profiles for the second                
trial is obstructed by large error bars demonstrated in the chitosan microsphere suspension. As observed               
with the 7-day experiment, silk presented a substantial amount of active lysozyme released, plateauing at               
approximately 60 μg for both suspensions, whereas chitosan showed very little active lysozyme release,              
plateauing at about 2 μg and 5 μg for suspensions 1 and 2. Again, the plateaus occur early in the time                     
frame at about day 3 which suggests that nearly all of the encapsulated protein is released early in the                   
tested time frame before day 10, which is far sooner than ideal for their intended application.  
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Figure 18:​ Total cumulative lysozyme released from 3 mg batches of SMC culture media over 11 days. 
Error bars reflect standard deviations of triplicate treatments taken within each timepoint. (A) Release 
profiles from first replicate set of microsphere suspension. (B) Release profiles from second replicate set 
of microsphere suspension. 
 
5.2.3 Phase II Conclusions 
After completing the methodology of Phase II, chitosan was eliminated, leaving silk as the best               
candidate material for microspheres with the intended design goal of the client. Chitosan was eliminated               
principally on the basis of microsphere yield and encapsulation efficiency, as well as review of               
shortcomings discovered from the results of Phase I and other previously known material  characteristics.  
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 Chitosan presented a lower microsphere yield percentage relative to starting fabrication material.            
As stated in one of the design objectives, for the sake of saving on supplies and reducing the likelihood of                    
having to fabricate microsphere batches more often, it is important that the proposed design has a high                 
yield. Though there was no statistical difference among the yield percentages calculated among the three               
loaded batches fabricated, this was likely due to the small sample size and the reduced weight of one of                   
the silk batches due to improper loading. This low calculated yield confirmed observations from SEM, for                
which only a few microspheres where visible on the mount.  
In addition to a low yield, chitosan also presented lower encapsulation efficiency of protein. One               
of the team’s design objectives was established to favor microspheres capable of holding large amounts of                
protein. This is important to the viability of our suggested design because, PDGF-BB, the protein that will                 
eventually be encapsulated into the microspheres for use in the IH model, is very expensive. Using                
microspheres with a high potential for encapsulating protein is one way to minimize waste of the growth                 
factor. Overall, silk presented a trend of increased encapsulation efficiency compared to chitosan. 
Though the release assays presented few conclusive findings regarding which microsphere           
offered a more sustained release up to ten days in suspension, the findings did provide more insight on                  
retention of protein activity. The release assays performed showed that a substantial amount of active               
protein is released from the silk microspheres, as opposed to the chitosan microspheres for which this                
could not be confirmed. Whether the chitosan microspheres presented little lysozyme release due to              
inactivation of the protein or lack of protein encapsulation, the silk microspheres presented a more               
promising release profile.  
In addition to the results gathered form Phase II, the team reassessed silk and chitosan for                
findings from Phase I methodology and other known characteristics. Chitosan presented more problems             
during fabrication than silk. Unlike silk, which did not require the use of an oil phase, chitosan droplets                  
were emulsified in olive oil during particle fabrication. This oil was difficult to remove and required a                 
series of centrifugation, decanting, washing and filtering steps which made the process tedious. In              
addition, after drying the chitosan particle onto filter paper, the particles appeared to clump together               
forming macroscopic flaky pieces which were difficult to dissolve. Difficulties that occurred throughout             
the fabrication process for chitosan microspheres shows that chitosan is less capable of meeting the design                
objective of easy fabrication. 
Ultimately, compared to silk microspheres, chitosan proved less compliant with team design            
objectives seeking efficient PDGF-BB encapsulation, and simplistic fabrication while maintaining a high            
yield. For these reasons, silk was chosen as the best candidate for releasing PDGF-BB into tissue rings for                  
an ​in vitro​ IH blood vessel model.  
 
6. Final Design Validation 
Silk microspheres were produced using silk fibroin solution, PVA, and ultrapure water. The             
material’s preparation was completed at room temperature. Before production, a model protein was added              
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 into the fibroin solution and mixed thoroughly. Once prepared, the material can be stored at 4​℃ as a                  
microsphere solution before incorporation of the microspheres into the TEBV ring molds to integrate within               
SMCs of the tissue rings.  
6.1 Economics  
There is an economic opportunity that exists for the development of a new, effective method to                
treat IH in the current market. The design and development of a microsphere capable of the sustained                 
release and local delivery of PDGF-BB to fabricated tissue rings could be beneficial for both research and                 
therapeutic purposes. The utilization of an inexpensive ​in vitro ​IH model can reduce the need for animal                 
testing and have significant economic impact on healthcare costs. The success of designing a              
PDGF-loaded microsphere capable of producing IH lesions could be used as an ​in vitro model for the                 
testing of therapies in development.  
6.2 Environmental Impact 
The production and operation of a PDGF-loaded microsphere would have a minimal impact on              
the environment. By using silk as the biomaterial in our final design, there would be no expected adverse                  
effects to the surrounding environment. Silk is a natural, non-toxic, biodegradable polymer that is FDA               
approved. Therefore, by using this material in our final design, the microsphere will be considered               
environmentally friendly and safe for clinical practice. 
6.3 Societal Influence 
The successful development and production of a controlled-release microsphere could have many            
benefits in society. As previously mentioned, the purpose of this design is to model human IH initiation                 
and progression for the testing of approved and experimental therapies. Using our model for the testing of                 
IH would also help with the understanding of the physiologic response to vascular tissue injury.               
Additionally, it could have potential benefits for the aid and treatment of patients who are affected by                 
vascular bypass, angioplasty, and stent failures, and thus could have a positive impact on improving the                
quality of life in society.  
6.4 Political Ramifications 
Currently in the United States, there is an ever increasing demand for improved healthcare. Areas               
such as stem cell research and regenerative medicine have received more attention in the medical field                
because of the potential benefits and capabilities that they inspire. There is also a growing need to combat                  
cardiovascular disease, since this specific type of illnesses is the leading cause of death in the United                 
States. The success of this model’s design and function could have many potential advantages and offer                
long-term possibilities in  medical research. 
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 6.5 Ethical Concerns 
​There are minimal ethical concerns in regards to the design and function of this system. Similar                 
to other contemporary models, the development of this system uses ​in vitro testing methods. This allows                
for experimentation to be conducted outside of living organisms and will primarily involve chemical              
compounds before pursuing animal-based studies. By using a controlled release microsphere to achieve             
the local delivery to engineered tissue rings, a successful model will be able to mimic the IH lesions                  
which occurs within human vascular tissue. Our approach has limited ethical concerns because animal              
models are not being used. However, this does not entirely eliminate the incorporation of animal subjects                
for future testing. Since the controlled-release microsphere will incorporate the natural polymer silk, there              
will be less ethical concerns regarding the testing procedure.  
6.6 Health & Safety Issues 
The overall design our controlled-release microsphere system has the potential to treat IH by              
investigating its initiation and progression. In the future, further studies can be performed to assess               
PDGF-BB’s incorporation into tissue rings. Following FDA regulations, extensive animal and clinical            
studies will need to be performed using this design. Our model will be tested with potential treatment                 
options to help identify what option is the most suitable. Silk is also a biodegradable material, minimizing                 
concerns of producing adverse by-products.  
6.7 Manufacturability 
The production of a PDGF controlled-release silk microsphere consists of materials that are easily              
accessible and a design that is easy to manufacture. Materials such as silk are expensive, available online                 
for approximately $200 for 50mg/mL. However, it can be purchased from many commercially available              
sources. The fabrication of silk microspheres takes approximately 6 hours. The microparticles can be              
stored in a 4℃ refrigerator for preservation in a microsphere suspension. Overall, there are minimal               
manufacturing difficulties for the final design of this sustained-release ​microparticle.  
6.8 Sustainability 
The components of the design comply with sustainability criteria by reducing the concern for              
waste and depletion of available resources. The fabrication of the microparticle does not require excessive               
materials or resources. Disposal of materials would not harm the environment as reagents such as silk,                
PVA, and Milli-Q water will be transferred to a chemical waste container once discarded. Silk is a natural                  
polymer which allows for easy availability and renewability of the material.  
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 7. Discussion 
Based on the desires of the client, the team was tasked with proposing an efficient way to deliver                  
growth factor from microspheres to a localized position of a TEBV in order to mimic IH for disease                  
modeling. The team therefore focused on determining an appropriate design material for such             
microspheres, as a starting point for the endeavor. Based on review of literature, the team decided to test                  
four promising materials for their aptitude with regard to meeting established constraints and objectives:              
gelatin, chitosan, PLGA and silk. After testing and comparing the different microsphere materials, the              
team concluded silk microspheres showed the most promise for the intended application and therefore              
recommends this material for further consideration as the client progresses towards the goal of              
constructing a TEBV model of IH.  
Throughout fabrication and testing of the microspheres, silk met the team’s design constraints.             
Because the microspheres are intended to be incorporated within toroids of SMCs, it is necessary that the                 
design materials be capable of being sterilized to allow for proper incorporation without contamination.              
They also must be biocompatible to allow for the cells to maintain function and morphology needed for                 
vessel integrity. All fabricated microspheres, including silk, were sterilized with ultraviolet radiation.            
Therefore all tested microspheres equally met this constraint. Once sterilized, the unloaded microspheres             
were tested for biocompatibility by conducting an MTT assay. Literature suggests all four materials are               
biocompatible with nearly all mammalian cell types. Silk, like the other three materials, showed              
significant decrease of smooth muscle cell viability in the assay. That said, the reductions in quantified                
metabolic activity decrease only slightly for each of the experimental groups, indicating that statistical              
significance likely arose from low variation among replicates of the same treatment. All materials affected               
cell viability in a very similar fashion. In all, the slight reduction in quantified cells in silk was not                   
deemed drastic enough to consider the material incompatible with the SMCs. 
The microsphere-based mechanism for achieving the desired lesion formation is contingent on the             
stimulation of cell proliferation from the release of growth factor. Because it is ultimately necessary to                
induce cell proliferation within the IH model, it is necessary that lysozyme, the enzyme used to model                 
PDGF-BB, is active once released from the spheres. The release assay was conducted not only to assess                 
the release profile of the fabricated particles but also to ensure that the loaded lysozyme remains active                 
once released. Silk did show positive enzyme-substrate absorbance quantities relative to blanks,            
suggesting at least a proportion of the lysozyme that was encapsulated and released was shown to be                 
active. Though the activity assay performed does prove some activity among the released protein, it               
cannot be determined for sure whether any observed lack of expected active lysozyme in the microsphere                
suspensions occurred as a result of inhibition of enzyme activity or release. Also, though active lysozyme                
was confirmed in the release suspension for the silk microspheres, it cannot be entirely confirmed that the                 
same trends would be seen with loaded PDGF-BB, though there is no reason to believe, based on the                  
literature review, that post-release activity would differ much depending on the protein used.  
In addition to adhering to established design constraints, silk met the design objectives better than               
the other tested microsphere materials. One design objective was a consistent and uniform particle size               
distribution. To better understand physical properties, such as particle size of the fabricated microspheres,              
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 the microspheres were imaged with SEM. The SEM images showed a very consistent diameter              
distribution, in relation to other materials with far greater observed size ranges. SEM also confirmed a                
consistent spherical morphology for the silk microspheres. It should be noted that the fabricated              
microspheres were smaller than he target size range determined by the team. Though their small size may                 
reduce the amount of PDGF-BB they are capable of carrying, they are still far bigger than 24.9kDa                 
PDGF-BB, which has a diameter on the order of nanometers. Therefore, silk being slightly beneath the                
target size range is not expected to hinder its function assuming it is still is able to achieve drug                   
encapsulation. 
Ideally, the microspheres can be fabricated with a high overall yield and high proportion of               
encapsulated drug. Silk showed a higher percent yield of loaded microsphere, relative to starting material,               
in contrast to chitosan, the other material still being considered in the protein-loading stages of               
experimentation. Of the fabrication yield measurements for silk microspheres, one showed a percent yield              
greater than the mass of the sphere components used during fabrication. Because this is not possible even                 
under ideal conditions, it can be assumed that this peculiarity arose due to error, perhaps from weighing                 
the microspheres before all of the liquid they were suspended in was dried off. An erroneous inflation of                  
fabrication yield was also seen in one chitosan batch, and after removing these outliers, silk still showed                 
higher encapsulation. The data therefore supports that silk provided better yield as there is no reason to                 
believe silk was weighed less accurately than was chitosan. Analyzing results from the encapsulation              
assay, all materials showed low encapsulation efficiency of lysozyme of less than 13%. This is likely due                 
to incomplete dissolving of the microspheres during preparatory stages of the assay, as they broke apart                
but remained visible in solution throughout the dissolving steps. This most likely occurred because the               
team sought out fabrication protocols yielding microspheres with minimal burst release of drug, which              
typically implies that they are resistant to quick degradation. Even though there was high likelihood of                
incomplete dissolution, encapsulation of active enzyme was confirmed through a statistically significant            
increase in active lysozyme in the silk samples compared to the blank negative control. Though not                
statistically significant, silk showed more lysozyme encapsulation than chitosan. All          
lysozyme-concentration data for silk were greater than those of chitosan, so absence of statistical              
significance likely came from the silk’s high data variance.  
Controlled release of growth factor from the microspheres was another important design objective             
which the team tested by conducting a lysozyme release assay. Minimal burst release and maximal release                
after ten days were the most important release-profile benchmarks, and were thus considered when              
comparing microsphere materials, Results of the 15-day assay showed increased active enzyme release             
from chitosan microspheres in comparison to silk, though these results were likely skewed due to               
unforeseen, improper loading of the tested silk batch as previously discussed. When the release assay was                
repeated, with properly loaded silk microspheres over a shorter time frame due to time restriction, an                
increase in total released lysozyme from silk was observed. These results are likely more indicative of the                 
microspheres’ ability to release a loaded protein like PDGF-BB, because greater active protein release              
from silk was seen in two successive 11-day release trials as well. Silk and chitosan microspheres                
presented a cumulative protein release plateau by as early as days 2 or 3 in the 7-day trial as well as in                      
both 11-day trials. Because both microsphere types exhibited an early burst release of protein, it was                
difficult to compare the two microsphere types on the basis of a release profile.  
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 To assure that the team’s proposed design is realistic, cost of materials and associated equipment               
was also considered when comparing the different microspheres. Fabricating silk microspheres posed            
little, if any, cost concern because it was supplied directly from another lab. This associated lab, which                 
produces silk and therefore has a steady supply, works closely with the lab of the client and may be a                    
continued source for materials for future model development. In the event that this lab does not provide                 
the materials, necessary for fabrication, silk-fibroin solution is available for online purchase at             
approximately $200 for 50mg/mL, making it one of the more expensive microsphere materials alongside              
PLGA. Consistency in results however, could reduce the amount of batches fabricated long-term,             
potentially offsetting the expense. The fabrication does not require any equipment that is not already               
available to the client.  
Constraints and objectives related to microsphere interaction with the SMC toroids were not able               
to be tested due to limited time. Therefore, it is still important to perform tests to ensure that the silk                    
microspheres can be incorporated within the toroids such that they remain long enough for growth factor                
release. They should also not disrupt the mechanical integrity or fusibility of the toroid, and growth factor                 
release should stimulate cell proliferation in the toroid.  
 
8. Conclusions and Recommendations 
The main objective of this project was to design a microsphere capable of sustained release and                
local delivery of PDGF-BB into tissue rings composed of murine SMCs to mimic the initiation and                
progression of IH lesions within vascular tissue. After conducting extensive research and testing with              
various biomaterials which possessed unique properties, silk was chosen for the final design because it               
had demonstrated the most conclusive results and was determined to be the most suitable material for                
fulfilling the goal of the project. Silk microspheres were successfully produced within a consistent range               
that fulfilled the size range stated in the objectives. The high resolution SEM images of the biomaterial                 
demonstrated that silk is capable of producing uniform microspheres. This can be achieved using a               
microfluidics device to alter the microparticle size to a desired range (Montoya, 2018) 
Silk demonstrated the capability to encapsulate chicken lysozyme, a test protein to PDGF-BB,             
and release it in its active form. Additionally, silk’s fabrication process was the least time consuming and                 
resulted in the fewest difficulties when compared to the other tested materials. The integration of silk                
microspheres into tissue rings was not completed due to time constraints, but the material is               
biocompatible and should not adversely affect cells.. 
Future testing for this project should include mechanical strength testing of the toroids with the               
incorporated silk microspheres and the final TEBV with the lesion. Mechanical testing could be              
completed through the use of an Instron machine, which would determine whether the addition of the silk                 
microspheres within the system significantly affects the mechanical strength when compared to the             
control. 
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 In addition, histological testing should also be conducted on the toroids incorporated with the silk               
microspheres. Histological testing will evaluate the effects that the microspheres will have within the              
toroid, and whether the microspheres will cause any adverse effects in maintaining the toroid and TEBV.                
Histology will also allow for measuring the effect that the growth factor will have on the TEBV after                  
release. 
The release profile assay should also be performed again with PDGF-BB instead of the lysozyme               
used within this testing. The lysozyme was used as a model for the PDGF-BB at a cheaper cost. However,                   
it is still unknown as to whether the release profile will vary with the loading of the growth factor. 
Further research into potential adaptations to the fabrication design of the silk microspheres             
should also be considered. Specifically, changes to the protocol which will allow for a greater               
encapsulation efficiency and further delayed release of the growth factor should be reviewed and studied.               
While silk offered the best encapsulation and release profiles out of the different tested design materials,                
optimizing these parameters would improve silk’s promise for use within the IH model. 
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 Appendices  
Appendix A: Acronym Glossary  
The following consists of a list of all acronyms used throughout the paper.  
 
● American Society for Testing and Materials  (ASTM) 
● Encapsulation Efficiency (EE) 
● Endothelial Cells (EC) 
● Fetal Bovine Serum (FBS) 
● International Standards Organization (ISO) 
● Intimal Hyperplasia (IH) 
● Phosphate Buffered Saline (PBS) 
● Platelet-Derived Growth Factor-BB (PDGF-BB) 
● Polyglycolic Acid (PGA) 
● Polylactic Acid (PLA) 
● Poly(lactic co-glycolic) Acid (PLGA) 
● Polypropylene (PPE) 
● Polyvinyl alcohol (PVA) 
● Scanning Electron Microscopy (SEM) 
● Smooth Muscle Cell (SMC) 
● Sodium Hydroxide (NaOH) 
● Three dimensional (3D) 
● Tissue Engineered Blood Vessels (TEBV) 
● Transforming Growth Factor Beta (TGF-β) 
 
Appendix B: Gelatin Microsphere Fabrication Protocol  
The following consists of the materials, expected yield percentage, and the procedure used for gelatin               
microsphere fabrication. 
Materials: 
● 4 mL 11.1 wt% acidic gelatin (Sigma Aldrich) 
● 100 mL olive oil 
● 100 mL chilled acetone  
● 1 wt% genipin - .05 mL 
● diH​2​O - 5 mL  
● Lysozyme ~ 80 ng/uL 
● PBS ~ 40uL 
● Stir plate and bar 
● Filter  
74 
 Procedure: 
Adapted from: Tabata, Y. et al., 1999 
1. 4 mL of 11.1 wt% acidic gelatin was added dropwise to 100 mL of olive oil and stirred at 45C  
2. After 10 minutes, the temperature was lowered to 20C for thirty more minutes  
3. Following the 30 minutes, 50 mL of chilled acetone is added to the solution and constantly stirred                 
for 1 hour  
4. Another 50 mL of acetone is added and the mixture is transferred from the stirrer and                
homogenized at 14,000 rpm for an additional 10 minutes 
5. Microsphere solution is centrifuged at 7,000 for five minutes or until the formation of a pellet.                
The oil is aspirated from the tube and the microspheres are washed with acetone. The process is                 
repeated three times, or until the entirety of the oil has been removed from the solution 
6. The microspheres are air dried overnight to evaporate any residual liquid from the surface 
7. Dry microspheres are added to aqueous solution of 2 mL 1 wt% genipin in diH​2​O at varying                 
times for varying levels of cross linking  
8. Microspheres collected, washed three times with diH​2​O and freeze dried  
9. Microspheres are UV sterilized for 10 minutes  
10. Sterile microspheres are then soaked in a solution of 80 ng/uL lysozyme/PDGF and PBS at a pH                 
7.4 for 2 hours at 37C. - Another protocol calls for vortexing of the solution without changing the                  
pH and incubating at 4 C for 15 hours  
 
 
Appendix C: Chitosan Microsphere Fabrication Protocol  
The following consists of the materials, expected yield, and the procedure used for chitosan microsphere               
fabrication. 
Materials: 
● Chitosan (40 mg) 
● Acetic Acid, 2% v/v (8 mL) 
● Genipin (2 mg) 
● Lysozyme (10 mg) 
● Olive Oil (150 mL) 
● Magnetic stir plate/rod 
● Homogenizer 
● Buchner funnel 
Procedure: 
Adapted from: Karnchanajindanun, J. et al., 2011 
1. Dissolve 40 mg of chitosan into 8 mL of  2% v/v acetic acid. 
2. Add 2 mg of genipin to the chitosan solution. 
3. Let sit for 6 hr while gently stirring.  
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 4. Dissolve 10 mg of lysozyme into the solution and stir for 10 min. 
5. Add the chitosan/lysozyme solution dropwise into 150 mL of olive oil. 
6. Stir the emulsion with a homogenizer at 1100 rpm for 1 hr. 
7. Transfer the emulsion to 50mL conical tubes and centrifuge at 200G for 5 minutes 
8. Remove as much of the supernatant oil as possible without disrupting the pellet.  
9. Transfer the remainder of the tube’s oil and chitosan pellet to a filter paper.  
10. Let the contents sit over a funnel and beaker overnight at 4C until almost all of the oil has passed                    
through the filter paper. 
11. Use forceps to transfer the filter paper to a clean funnel. 
12. Wash the filter paper with 5 mL of 70% isopropyl alcohol. 
 
Appendix D: Silk Microsphere Fabrication Protocol  
The following consists of the materials, expected yield, and the procedure used for silk microsphere               
fabrication.  
Materials:  
● 1 mL ~ 5 wt% silk fibroin solution 
● 4 mL ~ 5 wt% Polyvinyl alcohol (PVA) 
● Centrifuge device 
● Stirring plate 
● Vortex device 
● 32 mL ~ milli-Q water 
● 50 mL centrifuge tube 
● 50 mL glass beaker 
● 100 mm petri dish 
● PBS 
● 5 mg lysozyme  
Procedure:  
Adapted from: Wang X. et al., 2010 
1. 5 mg of lysozyme in 1 mL of PBS (pH 7.4) was added to the silk solution. 
2. 1 mL of 5 wt% silk solution and 4 mL of 5 wt% PVA solution were mixed together in a glass                     
beaker at a ratio of 1:4 to obtain a blend solution. 
3. The solution was transferred to an open 100 mm petri dish and mixed on a stirring plate at 150                   
rpm for 2 hours at room temperature. 
4. The dish was then dried for 3 hours in a fume hood. (Can leave overnight if necessary) 
5. The dried silk/PVA blend film was dissolved in 10 mL of milli-Q water by shaking the tube                 
gently at room temperature for 10 minutes and transferred to a 15 mL centrifuge tube.. 
6. The tube was centrifuged at 2,000 rpm for 20 minutes.  
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 7. Supernatant was carefully removed and the pellet was resuspended in 10 mL of milli-Q water and                
centrifuged once more. 
8. The supernatant was removed again and the pellet was resuspended in 2 mL of milli-Q.  
9. A vortex device was used to disperse the clustered silk microspheres for 15 seconds.  
10. The dispersed microspheres were stored at 4℃ (if necessary). 
 
Appendix E: PLGA Microsphere Fabrication Protocol  
The following consists of the materials, expected yield, and the procedure used for PLGA microsphere               
fabrication.  
Materials: 
● Resomer​®​ RG 858 S, Poly (D,L-lactide-​co​-glycolide) (85:15) 
● Polyvinyl Alcohol  (PVA) 
● Dichloromethane  
● PBS 
● Chicken lysozyme 
● DI water 
Procedure: 
Adapted from: 
 He, Z. et al., 2011. Koda, S. et al., 2017. Nafissi, N. et al., 2011. Li, L. et al., 2014 
1. Insert 1 mg of lysozyme into 250 µl of PBS. 
2. Invert mixture for ~2 min, and then mix at 1000 rpm for 5 min with stir bar. 
3. 250 mg PLGA powder is then added to 2.5 mL dichloromethane to make 10% oil  
4. Primary water phase from steps 1 and 2 and the above PLGA mix are then combined with                 
sonication (6W, speed knob set to 3) for 30 sec to form W/O emulsion. 
5. This emulsion is then mixed with 300 mL of 1.0% (w/v) PVA (already at between 4-10​°C​) with                 
homogenizer (setting at 2 speed) and then at 500 rpm for 3 hours in fume hood to make a                   
W/O/W.  
6. The dichloromethane should evaporate from the reaction mixture and microspheres should form 
7. Microspheres are then collected by running PVA solution through 60 mm filter paper in Buchner               
funnel.  
8. Wash and collect microspheres by rolling up filter paper into 50 mL conical tube and washing                
with 70 % isopropanol several times. Microspheres will collect at the bottom of the tube.  
9. Filter the microsphere-laden PVA solution through a filter and wash filter paper with isopropanol              
or water and collect runoff in a tube. 
10. Repeat step 9 three times, with runoff from the previous iteration used being filtered with fresh                
filter paper.  
11. Spin down microspheres at 5000 rpm for 30 minutes to collect a pellet.  
12. Store at -20​°C for short-term storage​ or freeze-dry for long-term storage.  
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Appendix F: MTT Assay Protocol  
The following consists of the materials and procedure used for the MTT Assay for biocompatibility. The                
procedure was adapted from an excepted protocol from the ​Cayman Chemical MTT Cell Proliferation              
Assay Kit Booklet.   
Materials: 
● Cayman Chemicals MTT Cell Proliferation Assay Kit  
○ MTT Reagent (25 mg) 
○ Assay Buffer 
○ Crystal Dissolving SDS (5 vials/1 g) 
○ Crystal Dissolving (hydrochloride) (5 vials/10 mL) 
● Adjustable pipette  
● 96 well plate for cell culturing  
● 96 well Colorimetric Microplate Reader  
● DI water 
● Shaker plate 
 
Procedure: 
1. Prepare the Assay Buffer by dissolving the cell-based assay buffer tablet provided with the kit in                
100 mL of DI water 
2. Prepare the MTT Reagent  
a. Dissolve 5 mg of MTT reagent in 1 mL of assay buffer through vortexing (This amount is                 
applicable for one 96 well plate. If more or less is being tested change values               
accordingly) 
b. Remove any undissolved material through filtration or centrifugation if applicable  
3. Prepare the Crystal Dissolving Solution  
a. Dissolve one vial of crystal dissolving SDS with one vial of crystal dissolving             
(hydrochloride). Both reagents are provided with the kit 
b. Mix well through vortexing  
c. Each vial is good for one 96 well plate  
4. Add 3 mg of respective microspheres into 1 mL of SMC culture media. Incubate the media at 37                  
C and 5% CO​2​ for 1 hour. 
5. Seed 50,000 cells/well in a 96 well plate 
6. After the hour incubation time, various amounts of the microsphere containing culture media will              
be added to the respective microsphere testing wells. The control and blank wells will contain               
normal SMC culture media. In total there should be 100 uL of volume per well  
7. Place cells in an incubator at 37 C for 24-48 hours  
8. Add 10 uL MTT reagent to each well 
9. Mix on shaker plate for 1 minute 
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 10. Incubate the cells for 3-4 hours  
11. Add 100 uL of crystal dissolving solution to each well and incubate for 4-18 hours until the                 
solution turns purple  
12. Measure the absorbance of each sample with the Microplate Reader at 570 nm 
  
Appendix G: Miscellaneous SEM Images 
Gelatin (2520x): 
 
Silk microspheres (3150x): 
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PLGA microsphere (2540x): 
 
 
Chitosan microsphere (610x): 
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Chitosan fragment (7400x): 
 
 
Gelatin with visible crosslinking (640x): 
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Two chitosan microspheres fused (620x): 
 
 
Chitosan surface (1100x): 
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PLGA microsphere (635x): 
 
 
Appendix H: Encapsulation Efficiency Protocol  
Gelatin Microsphere Encapsulation Efficiency 
Materials: 
● Distilled water (600 uL) 
● Loaded gelatin microspheres (3 mg) 
Procedure: 
Adapted from: Cortesi, et al., 1999  
1. Dissolve 3 mg of loaded gelatin microspheres in 600uL of distilled water and let sit for 72 hours. 
2. Run a lysozyme activity assay to determine the quantity encapsulated. 
3. Calculate encapsulation efficiency with the following equation:  
EE=[(quantified lysozyme)/(lysozyme initially loaded)]*100% 
Chitosan Encapsulation Efficiency  
Materials: 
● 2% Acetic Acid (500 uL) 
● Loaded chitosan microspheres (3 mg) 
Procedure: 
Adapted from: Zeng, et al., 2011  
83 
 1. Dissolve 3 mg of dried, loaded microspheres in 500 uL of acetic acid. 
2. Vortex the solution for 20 min at room temperature. 
3. Centrifuge the solution at 1000 rpm for 10 min. 
4. Add 60uL of 10x PBS to solution. 
5. Add 80uL of 1M NaOH to solution. 
6. Run a lysozyme activity assay to determine the quantity encapsulated. 
7. Calculate encapsulation efficiency with the following equation:  
EE=[(quantified lysozyme)/(lysozyme initially loaded)]*100% 
PLGA Encapsulation Efficiency 
Materials: 
● Dichloromethane (600 uL) 
● Loaded PLGA microspheres (3 mg) 
Procedure: 
Adapted from: Yang, et al., 2000  
1. Dissolve 3 mg of dried microspheres in 600uL dichloromethane into a glass container in the fume                
hood. 
2. Vortex the solution for 2 min. 
3. Run a lysozyme activity assay to determine the quantity encapsulated. 
4. Calculate encapsulation efficiency with the following equation:  
EE=[(quantified lysozyme)/(lysozyme initially loaded)]*100% 
Silk Encapsulation Efficiency 
Materials: 
● Deionized water (600 uL) 
● Loaded silk microspheres (3 mg) 
Procedure: 
Adapted from: Wen et al., 2011  
1. Dissolve 3 mg of loaded silk microspheres in 600 mL of deionized water. 
2. Vortex the solution for 2 min. 
3. Centrifuge at 4,000 rpm for 10 minutes.  
4. Run a lysozyme activity assay to determine the quantity encapsulated. 
5. Calculate encapsulation efficiency with the following equation:  
EE=[(quantified lysozyme)/(lysozyme initially loaded)]*100% 
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 Appendix I: EnzChek Lysozyme Assay Protocol  
The following consists of the materials and protocol used for the EnzChek Lysozyme Assay. The               
procedure was adapted from the ​EnzChek Lysozyme Assay Kit Manuals & Protocols ​from Thermo Fisher               
Scientific. 
Materials: 
● EnzChek Lysozyme Activity Assay Kit (E-22013) 
○ DQ Lysozyme Substrate (Component A) (1 mg ​Micrococcus lysodeikticus​) 
○ 1X Reaction Buffer (Component B) (50 mL buffer) 
○ Chicken Egg White Lysozyme (Component C) (1000 U) 
● DI water 
● Microplate Reader  
● 96 well plate  
● Adjustable pipette 
● Aluminum Foil 
Procedure: 
1. Prepare lysozyme substrate stock suspension  
a. Suspend the contents of the Component A vial in 1 mL DI water and mix  
b. This stock can be stored at 4 C for one month  
c. For six month storage add 2 mM sodium azide in single use aliquots of the solution and                 
freeze in -20 C freezer 
2. Prepare 1000 U/mL lysozyme stock solution  
a. Dissolve the contents of the Component C vial in 1 mL of DI water 
b. Lysozyme can be frozen in single use aliquots for six months to avoid freeze-thaw cycles  
3. Calculate standard curve  
a. Fill 8 wells with 50 ul of 1X reaction buffer (Component B)  
b. Add 50 uL of 1000 U/mL lysozyme stock solution to the first well and mix through                
pipetting 
c. Transfer 50 uL solution from first well to the second well  
d. Repeat this process until you reach the seventh well. Remove 50 uL from the seventh               
well and discard, adding nothing to the eighth well creating a range from 500 U/mL to 0                 
U/mL 
4. Dilute lysozyme samples in 1X reaction buffer and add 50 uL sample into each well. Dilution will                 
only be necessary if the activity is greater than the microplate readers ability and will therefore                
need to be optimized based on tests  
5. Dilute 1 mg/mL lysozyme substrate stock suspension 20-fold in 1X reaction buffer to prepare a               
50 ug/mL suspension. The amount of substrate stock suspension and reaction buffer used will              
vary based off of number of assays being run  
6. Add 50 uL of the 50 ug/mL lysozyme substrate solution to each well containing a sample for a                  
total well volume of 100 uL 
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 7. Incubate the plate for at least thirty minutes. Cover the plate in aluminum foil to eliminate                
exposure to light  
8. Measure fluorescence using the microplate reader  
a. Lysozyme substrate has an absorption maxima of 494 nm and a fluorescence emission             
maxima of 518 nm  
 
Appendix J: Lysozyme Release Assay Protocol  
A Lysozyme assay was chosen as the method for quantifying lysozyme released into solution over time                
for similar reasons as with encapsulation efficiency.  
Materials: 
● EnzChek Lysozyme Activity Assay Kit (E-22013) 
○ DQ Lysozyme Substrate (Component A) 
○ 1X Reaction Buffer (Component B) 
○ Chicken Egg White Lysozyme (Component C) 
● DI water 
● Rat smooth muscle cell complete media 
● 96 well plate  
● Adjustable pipette  
● Vortex 
● Colorimetric Microplate Reader 
Procedure: 
Adapted from: 
Zeng et al., 2011 
1. Dissolve 3 mg of dried, loaded microspheres into 6 mL of culture media (pH 7.4). 
2. Collect a 300 µl sample of the media and freeze at -20०C for later use in quantification. This will                   
act as the sample from the 0 day time point.  
3. Place samples in an incubator at 37०C. 
4. 24 hours later, centrifuge the sample at 1,500 rpm. 
5. Withdraw 300 µL from this supernatant and similarly freeze in -20०C. This will act as the sample                 
from the 1 day time point. 
6. Replace the removed media by adding 100 µl of fresh media. 
7. Redisperse the microspheres in the media solution and return to the incubator. 
8. Repeat the centrifuging, extracting, freezing, replacing process on predetermined collection days.  
9. Thaw the frozen samples. 
10. Perform a lysozyme activity assay exactly. 
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Appendix K: Encapsulation Assay Raw Data 
Test 1:  
● Using loaded batches fabricated at different time points 
● Most concentrated wells for standards (top row of plate map) contained 12.5% sample (either              
lysozyme stock), 37.5% reaction buffer, 50% substrate 
● Most concentrated wells for microspheres (first row) contained 12.5% sample, 37.5% reaction            
buffer, 50% substrate 
● Decreased concentrations were included by performing a 1:2 serial dilution from first row 
● Negative controls contain 25% solvent, 25% reaction buffer, and 50% substrate (should have no              
lysozyme) 
● Last row of standards acted as negative control blanks which lacked lysozyme, containing 50%              
reaction buffer, and 50% substrate 
● Plate map: 
 
● Raw absorbance data (yellow=high concentration, green=low concentration):  
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Test 2:  
● Using new dissolved samples from same batches assayed in Test 1 
● Most concentrated wells for microspheres (first row for PLGA and silk and fifth row for chitosan)                
contained 25% sample, 25% reaction buffer, 50% substrate 
● Chitosan dilutions begin on columns 4-6 of row 5, continue to row 6, then continue to columns                 
7-9 of row 5, then culminate at row 6 
● Positive controls contain 12.5% lysozyme stock, 25% solvent, 12.5% reaction buffer, and 50%             
substrate  
● Otherwise same conditions as specified in Test 1 
● Plate map: 
 
●   ​Raw absorbance data (yellow=high concentration, green=low concentration): 
88 
  
Test 3:  
● Using newly fabricated batches of loaded microspheres that were made just before the assay 
● Most concentrated wells for microspheres (first row for PLGA and silk and fifth row for chitosan)                
contained 25% sample, 25% reaction buffer, 50% substrate 
● 10x PBS and NaOH were added to the chitosan sample including the solvents of the positive and                 
negative controls for chitosan 
● Otherwise same conditions as specified in Test 2 
● Plate map: 
 
● Raw absorbance data (yellow=high concentration, green=low concentration): 
 
Test 4: 
● Using new dissolved samples from same batches assayed in Test 3 
● Otherwise same conditions as specified in Test 3 
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 ● Plate map: 
 
● Raw absorbance data (yellow=high concentration, green=low concentration): 
 
Test 4: 
● Using newly fabricated batches of loaded microspheres that were made just before the assay 
● Otherwise same conditions as specified in Test 4 
● Plate map: 
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● Raw absorbance data (yellow=high concentration, green=low concentration): 
 
Test 5: 
● Using samples from newly fabricated batches assayed  
● Tested new solvents (5% acetic acid and NaOH) for the microspheres (chitosan and silk,              
respectively) alongside the previously used solvents (2% acetic acid and DI water) 
● Increased dissolving time to 1 day 
● Otherwise same conditions as specified in Test 4 
● Plate map: 
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 ● Raw absorbance data (yellow=high concentration, green=low concentration): 
 
Test 6: 
● Using sample of silk microspheres from the same batch assayed in Test 5 
● Using a sample from a newly fabricated batch of chitosan 
● Reduced dissolving time back to that of the original protocol 
● Otherwise same conditions as specified in Test 4 
● Plate map: 
 
● Raw absorbance data (yellow=high concentration, green=low concentration): 
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 Appendix L: MTT Assay Raw Data 
Standard Curve 
Prior to experimentation with the unloaded microspheres, a standard curve was calculated with             
different cell densities to optimize the procedure based on the cell type. A 96 well plate was established                  
with cellular conditions as follows: 
● 0 cells/mL 
● 2500 cells/mL 
● 5000 cells/mL 
● 10,000 cells/mL 
● 25,000 cells/mL 
● 50,000 cells/mL 
● 100,000 cells/mL 
● 150,000 cells/mL 
 
This range was chosen based on recommended cell densities from the ​Cayman Chemical             
procedure. Three trials were set up for each condition and the MTT Assay Protocol was followed. The                 
absorbance was measured through the use of a spectrophotometer plate reader at 570 nm. A standard                
curve was established given the average measurements at each of the conditions and error bars were                
created with standard deviation calculations.  
● Standard curve graph given cell density conditions 
 
As seen in the figure above, the assay reached a saturation point beginning with the 100,000                
cells/mL density. This was shown through the larger standard deviation values starting at this and               
increasing conditions. For that reason, a value prior to the saturation threshold was chosen. Therefore,               
50,000 cells/mL was the cell density which was used for further experimentation. 
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 Using the established cell density condition, an MTT assay with the unloaded microspheres was              
performed for each of the four different microspheres. The protocol used followed the one found in                
Appendix F. The results from the assay can be seen below.  
● 96 well plate setup following incubation and prior to absorbance measurements. The conditions             
are blank, control, gelatin, chitosan, PLGA, and silk.  
 
Qualitatively, the expected color change within the assay from yellow to purple was seen in each                
of the different conditions with cells present. 
● Absorbance Measurements  
Test 1: 
 
Test 2: 
 
 
94 
 Test 3:  
 
Average Absorbance per Material: 
 
Appendix M: Release Assay Raw Data 
Test 1:  
● Using samples from loaded batches of chitosan and silk (both properly loaded) 
● 7-day duration of suspension 
● Dilutions (1:5) of two latest time points also included for each material 
● Positive controls contain media, lysozyme stock, and reaction buffer 
● Negative controls contain media and reaction buffer 
● Based on release profile analysis and review of the procedure, it was discovered that substrate               
was unintentionally forgotten 
● Plate map: 
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● Raw Data:  
 
● Standard Curve: 
 
Test 2:  
● 15-day assay and redo of 7-day assay where all samples are diluted 1:5. 
● Fewer standard concentrations were used. 
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 ● Based on release profile analysis of the 15-day assay and review of the encapsulation assessment               
of microspheres from the same batches used, it was discovered that the silk microspheres tested               
were not loaded properly. This error did not apply to the 7-day batch which used different                
microsphere batches. 
● Plate map: 
 
● Raw Data:  
 
● Standard Curve: 
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Test 3:  
● Newly prepared batches of chitosan and silk microspheres used 
● 11-day assay where all samples are diluted 1:5. 
● Otherwise the same as Test 2. 
● Plate map: 
 
● Raw Data:  
 
● Standard Curve: 
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Test 4:  
● Microsphere samples taken from the same batches used in Test 3 
● 11-day assay where all samples are diluted 1:5. 
● Repeat of Test 3, ran concurrently. 
● Plate map: 
 
● Raw Data:  
 
● Standard Curve: 
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